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ABSTRACT 
Obesity, especially excess amount of abdominal fat, predisposes to a high risk for 
cardiovascular disease. Cancer cachexia is characterized by a specific loss of white adipose 
tissue (WAT) and skeletal muscle mass, and is associated with decreased survival and poor 
response to chemotherapy. We hypothesize that alterations in WAT function contribute to the 
negative metabolic consequences and disease outcome, respectively, of these two disorders. In 
this thesis we apply global transcriptome profiling on patient abdominal WAT biopsies to 
identify new genes and pathways of relevance for WAT function. In particular we explore gene 
expression in relation to (i) WAT depot, (ii) a dietary intervention study, and (iv) cancer with or 
without cachexia. In addition, we select one gene from microarray, Follistatin, for detailed 
expression profiling and functional evaluation in human fat cells.  
In the first study, we successfully set up Representational difference analysis to 
identify a handful of genes differentially expressed between subcutaneous and visceral WAT, 
e.g. Adipsin, a component in the complement system, and Phospholipids transfer protein 
(PLPT), which is involved in transfer of phospholipids between lipoproteins. Our second study 
was part of a large consortium which compared the effects of a ten week intervention with a 
low-fat, high-carbohydrate hypoenergetic diet versus a moderate-fat, moderate-carbohydrate 
hypoenergetic diet. Both diets produced similar weight loss and beneficial changes in blood 
chemistry parameters. We performed abdominal subcutaneous WAT global transcriptome 
profiling on a subgroup of patients before and after the dietary intervention. The expression of 
96 genes was significantly influenced by hypocaloric diet. Expression of genes involved in the 
synthesis of polyunsaturated fatty acids was downregulated, and CIDEA was up-regulated by 
hypocaloric diet. The pattern of gene expression response was almost identical between the two 
diets. In the third study we report that subcutaneous WAT Follistatin mRNA decreases with 
increasing weight, and that weight loss restores Follistatin levels. Furthermore, Follistatin is 
primarily produced by cells of the stroma vascular fraction in WAT. We show that WAT 
secretes Follistatin in vitro. Treating precursor cells with Follistatin in vitro stimulates 
adipogeneisis. We cotreated precursor cells with Follistatin and Myostatin under adipogenic 
conditions, and found that cotreatment reversed the inhibitory effect of Myostatin on 
adipogenesis. The fourth study compared cancer patients with or without cachexia. Global 
transcriptome profiling revealed that genes downregulated by cachexia were overrepresented in 
pathways related to extracellular matrix, actin cytoskeleton and focal adhesion. By contrast, 
genes upregulated in cachexia were overrepresented in pathways related to energy turnover, e.g. 
fatty acid degradation, and oxidative phosphorylation.  
In conclusion, variation in WAT size is associated with changes in tissue 
morphology, fat cell number and metabolism, as well as adipokine secretion. We provide 
support that the dietary energy intake, and not the macronutrient composition, is associated with 
changes in WAT gene expression, and highlight the role of CIDEA, which subsequently has 
been shown to be an important regulator of metabolic switch in fat cells. We identify Follistatin 
as a new adipokine. Insufficient Follistatin in obesity could possibly contribute to a 
hypertrophic WAT with large insulin resistant fat cells. We provide support that cachexia is 
associated with changes in WAT remodeling, which could be involved in WAT loss in this 
clinical condition.  
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1 INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
The ongoing world-wide obesity epidemic has spurred research to investigate the 
function of white adipose tissue (WAT). WAT, which previously was regarded as an 
inert store of energy, is now considered an active participant in regulation of whole 
body metabolism, which signals to other organs by secreting hormones and metabolites 
(Wajchenberg et al, 2009). Furthermore, WAT is extremely plastic – no other organ 
can change its volume as dramatically as WAT. Such change in fat mass is associated 
with large alterations in WAT cellular phenotypes. The regulation of WAT cellular 
function, depot differences and how WAT is influenced by two states of fat mass loss, 
i.e. hypocaloric diet and cancer cachexia, is the focus of this thesis. Below is given a 
brief introduction to obesity, human WAT function, approaches to voluntary weight 
loss by caloric restriction, and cancer cachexia. 
 
1.2 OBESITY AND COMORBIDITIES 
Obesity is a worldwide epidemic and predisposes to a high risk for premature mortality. 
Especially abdominal obesity is a well-known risk factor for the occurrence of 
cardiovascular disease (Yusuf et al, 2005) and premature mortality (Pischon et al, 
2008); it is related to metabolic changes, such as dyslipidemia, hypertension, type 2 
diabetes mellitus (T2D), inflammation and hypercoagulability. An easy approximative  
appreciation of abdominal obesity can be obtained by measuring waist circumference 
or waist hip ratio (WHR) (Shuster et al, 2012). There is an association between waist 
circumference or WHR and mortality, even in normal weight persons (Pischon et al, 
2008; Ruderman et al, 1998). Also several malignancies are associated to obesity such 
as prostate, breast and colorectal cancer (Basen-Engquist & Chang, 2011; Kaidar-
Person et al, 2011; Trinchieri, 2011). 
 
It is widely accepted that the manifestations of the metabolic syndrome cluster of 
diseases depends of continued exposure to environmental factors, mainly diet and lack 
of exercise, modulated by genetic factors (Dahlman & Arner, 2010). Recent studies 
reveal also possible epigenetic influence (Herrera et al, 2011; Steger et al, 2010). 
Obesity is highly correlated with insulin resistance (Gregor & Hotamisligil, 2011), but 
both insulin resistant lean individuals and metabolically healthy obese individuals 
(Wildman, 2009) are well recognized by the clinician. A recent study comparing 
insulin resistant individuals with insulin sensitive subjects with the same BMI showed 
far more gene expression changes in adipose than in muscle suggesting a more 
important role for altered adipocyte transcription in impaired insulin action (Elbein et 
al, 2011).  
 
1.3 WHITE ADIPOSE TISSUE CHARACTERISTICS 
1.3.1 Cellular composition 
With the escalating incidence of obesity a better understanding of adipose metabolism 
and techniques to quantify and characterize obesity are necessary (Shuster et al, 2012). 
WAT is a heterogeneous organ composed of mature adipocytes and the stromavascular 
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fraction (SVF), which includes mostly precursor cells, endothelial cells, fibroblasts, 
macrophages and lymphocytes. Each cell type may contribute to secretion from WAT. 
Adipose tissue growth results from two processes: the increase in number of adipocytes 
(hyperplasia) that develop from precursor cells, and the growth of individual fat cells 
(hypertrophy) due to incorporation of triacylglycerides (TAGs). The risk of metabolic 
complications is increased not only by the amount and location of WAT, but also by 
the size of the fat cells. Human fat cells can change ׽20-fold in diameter and several 
thousand-fold in volume. Enlargement of subcutaneous abdominal adipocytes is 
associated with insulin resistance and is an independent predictor of T2D (Weyer et al, 
2000). It is also shown that hypertrophic adipose cells display distinct gene expression 
profile compared to small cells (Jernas et al, 2006). Gene expression profile in 
adipocytes has also been compared to that of the SVF (Cancello et al, 2005). 
Adipocytes transcripts have well known metabolic and secretory properties while genes 
from SVF often belong to ‘inflammatory’ or ‘immune’ processes. 
 
Spalding et al have recently shown that the total number of adipocytes increases only in 
childhood and adolescence and stays constant in adults. The annual turnover was 
appreciated to be approximately 10% (Spalding et al, 2008). Low generation rates of 
new adipocytes associate with WAT hypertrophy, whereas high generation rates 
associate with adipose hyperplasia (Arner et al, 2010). In morbid obesity, WAT 
hyperplasia with many small adipocytes is mainly associated with better glucose, 
insulin, and lipid profiles as compared to WAT hypertrophy with large adipocytes 
(Hoffstedt et al, 2010).  
 
 In the last years much attention has been focused on the WAT macrophages whose 
accumulation is correlated with extent of obesity and insulin resistance (Anderson et al, 
2010; Weisberg et al, 2003). The metabolic syndrome, visceral adiposity and T2D are 
characterized by a low grade chronic inflammation in WAT, which is associated with 
altered lipoprotein metabolism and insulin resistance in the liver (Cancello et al, 2006). 
WAT from obese insulin resistant rodents and humans are characterized by increase in 
inflammatory macrophages and also fibrosis and increases in components of extra 
cellular matrix (Henegar et al, 2008). Obese insulin-resistant subjects have fewer 
capillaries and more large vessels in WAT as compared with lean subjects (Spencer et 
al, 2011). Hypothetically the extracellular matrix of adipose tissue may play an 
important role in regulating the expandability as well as angiogenesis of WAT. 
 
1.3.2 Adipose Lipid turnover 
WAT has a unique ability to adapt its size in response to calorie excess or depletion. 
Adipocytes are well equipped for storing energy as TAG in a large lipid droplet. 
Lipolysis is the breakdown of TAG into free fatty acids and glycerol (Arner, 2005). 
Adipose triglyceride lipase catalyzes the first step (formation of diglycerides), and 
hormone-sensitive lipase (HSL) catalyzes further hydrolysis to generate the end 
products fatty acids and glycerol. Free fatty acids and glycerol can be used as energy 
rich fuels in catabolic situations. There is a low basal lipolysis in adipocytes, that is a 
continuous breakdown of TAG. The major physiological stimuli of lipolysis are 
catecholamines and the major inhibitor insulin. Catecholamines bind to stimulatory 
beta adrenoreceptors on the adipocytes, which via a G-protein mediated pathway 
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phosphorylates HSL which is the rate-limiting step in lipolysis. Catecholamines can 
also bind inhibitory alpha adrenoreceptors.  
Abdominal subcutaneous adipocytes are more sensitive to insulin, and not as 
lipolytically active as the visceral WAT depot. The beta adrenoreceptors are more 
active in the visceral adipocytes, while the inhibitory alpha 2 adrenoreceptor and insulin 
are more active in the subcutaneous adipocytes (Arner, 1995). The differences in 
lipolytic activity are even more pronounced in obesity.  
 
Lipogenesis is the process of synthesizing TAGs. Fatty acids either originate from 
previous lipolysis in adipocytes, or are taken up from the blood. In addition, glucose 
needs to be taken up from the blood to form the glycerol backbone. It can also be used 
to synthesize fatty acids. 
 
Mitochondria are cell organelles with a central role in energy turnover. In the 
mitochondria the beta oxidation of fatty acids, the tricarboxylic acid cycle (TCA), and 
oxidative phosphorylation take place. The beta oxidation and glycolysis converge onto 
the TCA, by which energy rich electron donors are formed. Subsequently, these energy 
rich donors are used in the electron transport chain, or oxidative phosphorylation 
pathway, to synthesize energy rich adenosine triphosphate. 
 
It is established that mitochondrial function in skeletal muscle is impaired in human 
T2D individuals (Mootha et al, 2003; Petersen et al, 2003). This finding has evoked 
interest in WAT mitochondria function as well. It has been shown that glitazones 
increase mitochondria number and fatty acid oxidations in adipocytes (Bogacka et al, 
2005) (Boden et al, 2005). An important transcriptional regulator of mitochondrial 
biogenesis and the enzymes of the electron transport chain is Peroxisome proliferator-
activated receptor coactivator 1-alpha (PGC1A). Overexpression of PGC1A in human 
adipocytes increased the fatty acid oxidation capacity of the cells (Tiraby et al, 2003).  
 
1.3.3 White adipose tissue secretory function 
After the discovery of Leptin in 1994 (Zhang et al, 1994), WAT was no longer 
considered an energy reservoir only; the concept of WAT as a real endocrine organ was 
now established. Since then it has been accepted that WAT plays a vital role in 
regulating energy and glucose homeostasis (Kahn & Flier, 2000) by producing a 
number of biologically active proteins that are called adipokines. These adipokines 
have functional roles in diverse processes including glucose homeostasis, lipid 
homeostasis, appetite regulation, immune function, hormonal processes, angiogenesis 
and blood pressure control (Trayhurn & Wood, 2004). True adipokines are secreted 
from adipocytes but in WAT there are also other cell types secreting peptides.  
 
In 1993 it was reported that Tumor necrosis factor-α (TNF-α) is overexpressed in the 
WAT of obese mice, which provided the first clear link between obesity, diabetes and 
chronic inflammation (Hotamisligil et al, 1995). In 2003, it was recognized that 
increased inflammation and macrophage infiltration accompany the expansion of WAT 
(Weisberg et al, 2003) and since then numerous studies showing obesity-related 
inflammation have been published. Many suggest an association between the 
inflammation and insulin resistance (Arner, 2007; Wajchenberg et al, 2009). Activated 
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macrophages in WAT secreting Interleukin 6 and TNF-α may lead to endothelial 
dysfunction and insulin resistance in parallel with accelerated arteriosclerosis 
(Anderson et al, 2010; Vykoukal & Davies, 2011). WAT macrophages and 
inflammation have been associated with obesity-related co-morbidities such as 
cardiovascular disease (Apovian et al, 2008), liver steathosis (Cancello et al, 2006) and 
T2D (Donath & Shoelson, 2011). The hereditary component of WAT inflammation 
seems to be strong, since even in young nonobese  healthy first degree relatives of T2D 
patients a low grade inflammation is measurable and is aggravated by physical 
inactivity (Hojbjerre et al, 2011).  
 
Recent extensive studies of secreted proteins in human adipose shows that there are still 
numerous new adipokines to characterize (Lehr et al, 2012). There is a continuous 
crosstalk between different tissues in the body where adipocytes can secrete substances 
acting locally or systemically on e.g. myocytes to reduce insulin sensitivity and 
myokines can effect adipose tissue (Trayhurn et al, 2011). 
 
1.3.4 Subcutaneous and omental white adipose tissue 
WAT from different regions of the body expresses different subsets of genes and 
displays distinct metabolic properties (Arner, 1998; Lafontan & Girard, 2008). WAT 
from intraabdominal depots (omental and mesenteric) is regarded different from 
subcutaneous WAT (femoral, gluteal, abdominal).  Lipolytic rates in omental and 
subcutaneous WAT are different; omental WAT displays a low basal lipolysis while 
the catecholamine-stimulated lipolysis is increased compared with subcutaneous WAT 
(Arner, 1995). Recently it was shown that the catecolamine-stimulated lipolysis in 
omental adipose is 40% higher in metabolic syndrome than in healthy obese women 
(Andersson et al, 2011). Omental tissue is more extensively vascularized than 
subcutaneous WAT (Arner, 1995; Dicker et al, 2009). Adipocyte size has been reported 
to be larger in visceral than in subcutaneous WAT but opposing reports exist (Villaret 
et al, 2010). 
 
Many, but not all, studies show a stronger association between visceral than 
subcutaneous WAT and metabolic disease. The Health, Aging and Body composition 
study (Nicklas et al, 2004) on 2500 elderly persons found an association in women 
between visceral adipose area and incidence of acute myocardial infarction. The 
Framingham Heart Study (Fox et al, 2007) reported that volumetric CT measures of 
both subcutaneous and visceral WAT were correlated with multiple metabolic risk 
factors, although risk factor correlations with visceral WAT were consistently 
significantly stronger than those for subcutaneous WAT. There was also a stronger 
association in women between metabolic risk factors and visceral WAT. A recent study 
by Smith (Smith et al, 2012) showed that visceral, but not subcutaneous, abdominal 
adiposity is strongly related to cardiometabolic risk factors and to the prevalence of 
cardiovascular disease, independent of presence of diabetes. Visceral WAT is a 
stronger correlate of insulin resistance than subcutaneous WAT (Preis et al, 2010). 
Coronary artery disease patients was recently shown to have an 25% increased risk for 
vascular mortality and 15 % increased risk of all-couse mortality with 1 cm increase in 
intraabdominal WAT (Kanhai et al, 2011). 
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A number of mechanisms have been proposed to explain the association between 
visceral WAT and metabolic disease. Omental WAT is drained by the portal venous 
system so adipokines, cytokines and free fatty acids from this fat depot directly impact 
liver metabolism. Omental WAT is more extensively vascularized than subcutaneous 
WAT and has a higher capillary network density (Villaret et al, 2010). Recent studies 
(Gealekman et al, 2011; Ibrahim, 2010) propose that subcutaneous WAT has a higher 
capacity to expand its capillary network than visceral WAT, but this capacity decreases 
with morbid obesity. The decrease correlates with insulin resistance, suggesting that 
impairment of subcutaneous WAT angiogenesis may contribute to metabolic disease 
pathogenesis. Investigations of adipocyte precursors from different depots suggest that 
the differences exist from embryogenesis through adipogenesis to the functional 
differences of mature adipocytes. Each depot has its unique pattern of developmental 
gene expression (Gesta et al, 2007; Tchkonia et al, 2007).  
 
Furthermore, Harman-Boehm and others have shown that elevated macrophage 
infiltration in omental versus subcutaneous WAT exists in lean subjects and is 
exaggerated by obesity, particularly if predominantly intraabdominal (Bruun et al, 
2005; Cancello et al, 2006; Dahlman et al, 2005). The number of omental macrophages 
correlates with waist circumference and metabolic syndrome parameters (Harman-
Boehm et al, 2007), as well as hepatic fibroinflammatory changes (Cancello et al, 2006) 
potentially linking central adiposity with increased risk of diabetes and coronary heart 
disease (CHD). 
 
1.3.5 Gender impact on white adipose tissue 
There are gender differences in regional fat distribution. Already in 1947 Jean Vague 
presented detailed studies of the differences in WAT distribution between men and 
women (Vague, 1947; Vague, 1956). Based on these differences he could classify 
obesity into an android and a gynoid type. The android type has more central, 
abdominal fat whereas the gynoid type has a generalized fat distribution with more 
gluteofemoral WAT at the hips. Vague couples android obesity with diabetes and 
cardiovascular disease. Later studies have confirmed and extended his observations that 
premenopausal women have more subcutaneous WAT whereas men have more 
visceral fat. (Lemieux et al, 1994; Nedungadi & Clegg, 2009; Wajchenberg et al, 
2002). This may be one reason why the incidence of obesity-related metabolic 
disorders is much lower in premenopausal women than men. A Dutch study examining 
body composition in 2506 individuals found sex-specific genetic effects underlying 
several body composition traits (Zillikens et al, 2008). Furthermore, there are 
differences in both subcutaneous and visceral adipocyte lipolysis between genders 
(Lofgren et al, 2002; Lonnqvist et al, 1997) 
 
Interestingly, in a recent large metaanalysis of genome wide association studies many 
genetic loci associated with WHR displayed a gender specific effect (Heid et al, 2010). 
Some gene expression studies have shown gender differences in gene expression for 
the same fat depot suggesting hormonal control of these genes (Klaus & Keijer, 2004). 
One example is the extracellular matrix glycoprotein THBS1. THBS1 is an activator of 
the transforming growth factor, which in turn is an inducer of the inhibitor of 
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plasminogen activator inhibitor 1 (PAI-1). THBS1 was overexpressed in visceral fat 
only in males (Ramis et al, 2002). 
 
1.4 IMPACT OF DIET ON WAT 
While the beneficial effects of weight loss in obesity are evident, regulatory 
mechanisms in WAT that stand behind these effects are not well established. The 
search for patho-physiological mechanisms has been stimulated by the finding that 
obese states are likely to be low-grade inflammatory states. Voluntary weight loss can 
be achieved by life style changes, e.g. increased physical activity, reduced energy 
intake, pharmacological  agents, liposuction, and bariatric surgery. Long term 
successful weight loss remains a challenge (Turk et al, 2009). However, it is clear that 
weight loss has beneficial impact on health and survival (Anderson & Konz, 2001; 
Tsigos et al, 2008). This thesis is limited to study the effects of hypocaloric diet and 
macronutrient content of diet, which are described in more detail. 
 
1.4.1 Hypocaloric diets 
The importance of the composition and amount of energy restriction of a diet for the 
prevention and management of obesity is debated. Several studies have been published 
regarding the effect of diet macronutrient composition on weight reduction. Ad libitum 
consumption of low fat diets result in short-term weight loss (Astrup et al, 2000) and 
low-carbohydrate, high-protein and high-fat diets may give substantial weight loss as 
compared with other diets (Gardner, 2007). Because of their satiating and thermogenic 
properties, high-protein diets have been prescribed for both body weight loss and 
maintenance (Brinkworth et al, 2004; Paddon-Jones et al, 2008). Recently, Sachs 
(Sacks, 2009) in a large study showed no difference between dietary fat, protein, or 
carbohydrate content on weight loss with the main effect caused by energy restriction. 
 
In parallel, research has also focused on the type of carbohydrates in diets. The 
glycemic index (GI) refers to the postprandial blood glucose response expressed as a 
percentage of the response to an equivalent carbohydrate portion of a reference food, 
such as white bread or glucose (Wolever et al, 1991). Reducing the insulin response by 
lowering the GI in diets may lead to an improved blood glucose profile over the late 
postprandial period (Brand-Miller et al, 2002), which may be translated into a better 
appetite control and possibly different metabolic consequences. A Cochrane review of 
randomized controlled trials with low GI-diets showed that overweight or obese people 
on a low GI diet lost more weight than overweight or obese people on control diets 
(Thomas et al, 2007). Low GI combined with higher intake of unavailable 
carbohydrates leads to lower fasting glucose, higher  insulin sensitivity and lower  
HbA1c in individuals at risk for obesity, T2D, and CHD (Livesey et al, 2008). 
 
Also the prospects for weight maintenance has to be taken into account (Barte et al, 
2010; Turk et al, 2009; van Dam & Seidell, 2007). Recently Marquez-Quinon 
(Marquez-Quinones et al, 2010) identified subcutaneous WAT gene expression patterns 
that discriminated successful weight control from weight regain over a 6-month period 
in weight-reduced obese women.  
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Very low calory diet (VLCD) and low calory diet (LCD) are common prescriptions in 
weight loss programs. VLCD is often a liquid formula supplying 800 kcal/day. It has 
since long been known to improve metabolic profile (Hainer et al, 1992). LCD is the 
individuals energy requirement minus approximately 600 kcal/day. 
 
1.4.2 Impact of voluntary weight loss on WAT function 
Since WAT is the organ most strongly affected by weight loss, it is likely that changes 
in WAT function are key mediators of the beneficial effect of weight loss on health and 
survival. Effects of weight loss, by either bariatric surgery or hypocaloric diet have 
been reported in a number of studies recently reviewed by Klimcakova (Klimcakova et 
al, 2010). The catabolic state associated with hypocaloric diet is, as expected, 
associated with increased lipolysis as free fatty acids are mobilized from WAT (Stich et 
al, 1997). By contrast, Löfgren et al has shown that adipocyte lipolysis are lower than 
in weight matched controls in the late weight stable phase following intense weight loss 
by behavioural modifications or bariatric surgery(Lofgren et al, 2005b). Insulin 
sensitivity return to the same level as in controls. Adipose tissue hypercellularity  
(many small fat cells) and low Leptin production were observed in the postobese state 
(Lofgren et al, 2005a). 
  
As regards gene expression in WAT, Clement et al used gene expression profiling 
using 43000 cDNA clones to investigate changes in subcutaneous WAT expression 
during a 4-week VLCD (Clement et al, 2004). 10 obese subjects were investigated 
before and after VLCD. Six nonobese were used as controls. Expression of 170 genes 
changed by VLCD, most of them (60%) belonging to the metabolism gene ontology 
category. There was also 100 inflammation related genes that were affected by weight 
loss. Examining isolated adipocytes and the SVF showed that most of the inflammation 
related genes were expressed in the SVF in resident activated macrophages. The 
improving effect of weight reduction on WAT gene expression seems to be rapid. Two 
weeks of VLCD in obese patients with and without T2D decreased expression of 
chemotactic and proinflammatory factors in WAT but even faster and more 
pronounced in peripheral monocytes (Mraz et al, 2011). Follow up studies in other 
populations have found that hypocaloric diet and weight loss are accompanied by a 
reduction of macrophages in WAT (Kovacikova et al, 2011).  
 
 In addition, the temporal response of WAT gene expression to weight loss has been 
investigated. Capel F et al has shown that a period of energy restriction by VLCD is 
accompanied by reduced expression of metabolic genes and increased expression of 
inflammatory genes (Capel et al, 2009). This pattern is reversed after a period of weight 
stabilization. When they compare the patients before VLCD, and 4 months after in 
weight maintenance phase, there is no changes in metabolic genes expression but 
decreased inflammatory profile. This possibly indicates that the patients’ have reached 
a new metabolic steady state with a lower weight, which results in less inflammation in 
WAT. Not surprising it becomes evident that the timepoint is important when studying 
WAT gene expression changes. 
An exhaustive review of dietary intervention studies investigating adipokines at mRNA 
and protein level between 1996-2009 was published by Klimcakova 2010. The overall 
finding is that dietary interventions leading to 5-10% weight loss modulate production 
 8 
of certain adipokines and generally induce improvements of clinical parameters, e.g. 
insulin sensitivity. 
 
1.4.3 Impact of macronutrients on WAT function 
The macronutrient composition of diet determines the risk of cardiovascular risk in 
humans. However, there is insufficient data as to whether the macronutrient 
composition of diet influences WAT phenotypes in humans. Diets rich in whole-grain 
cereals and food with a low glycemic index may protect against  T2D (Schulze et al, 
2004). It is also found that dietary resistant starch may improve insulin sensitivity 
(Robertson et al, 2005).The FUNGENUT Study compared in patients with the 
metabolic syndrome dietary carbohydrate modification with increased intake of rye and 
pasta with a low GI, as compared to oat wheat and potato with a high GI. The diet rich 
in rye and pasta with a low GI improved early insulin response(Laaksonen et al, 2005) 
and modulated gene expression in subcutaneous WAT, even in the absence of weight 
loss(Kallio et al, 2007). Genes regulating insulin signaling and apoptosis were 
downregulated during the ryepasta diet, and genes mainly related to metabolic stress 
were upregulated during the oat-wheat-potato diet. 
 
In abdominally obese patients an eight week trial comparing two diets differing in fatty 
acid composition but with normal energy content was performed measuring impact on 
metabolic parameters and subcutaneous WAT gene expression profile(van Dijk et al, 
2009). Consumption of a diet rich in satuarated fatty acids (SFA) resulted in a 
proinflammatory “obesity-linked” gene expression profile , whereas consumption of a 
diet rich is monounsaturated fatty acids (MUFA) caused a more anti-inflammatory 
profile in spite of unchanged adipose morphology and insulin sensitivity.  
 
1.5 CANCER CACHEXIA 
Cachexia is derived from the Greek words kakos and hexis meaning “bad condition”. It 
is a syndrome with weight loss, reductions in skeletal muscle and WAT mass, anorexia 
and weakness, and is frequently associated with inflammation and insulin resistance. It 
usually occurs in chronic diseases such as cancer, chronic heart failure, chronic 
obstructive lung disease and end stage renal failure. Cancer cachexia is a wasting 
disorder seen in half of untreated cancer patients (Blum et al, 2011; Deans & Wigmore, 
2005; Fearon & Moses, 2002).The diagnosis cancer cachexia involves involuntary 
weight loss >5% over the past 6 months or BMI <20 and weight loss >2% (Fearon et al, 
2011).  Cancer cachexia is associated with a specific loss of WAT and skeletal muscle 
mass, decreased survival, and poor response to chemotherapy (Esper & Harb, 2005). 
Hyper-metabolism can only partly explain the loss of weight (Bosaeus et al, 2001). The 
mechanisms behind tissue loss in cancer cachexia are unknown, but are thought to 
derive from multiple metabolic alterations, such as reduced appetite, increased energy 
expenditure and tissue breakdown. The main affected tissues are skeletal muscle and 
WAT.  
 
1.5.1 Cancer cachexia in white adipose tissue 
Recent studies have begun to explore the mechanisms that contribute to WAT loss in 
cancer cachexia. Increased lipolysis and fatty acid oxidation have been demonstrated in 
WAT of patients with cancer cachexia (Agustsson et al, 2007).  The lipolysis increases 
via raised levels of HSL, which is the rate limiting step in lipolysis (Ryden et al, 2008). 
Increased fatty acid oxidation is partly mediated by Cell death-Inducing DFFA Effector 
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A (CIDEA) (Laurencikiene et al, 2008b).(Laurencikiene et al, 2008b). Systemic 
inflammation is found in human cachexia; however, WAT levels of cytokines, or 
leukocyte and macrophage markers are not altered (Ryden et al, 2008). In muscle of 
cancer cachexia patients an increased expression of genes regulating the ubiquitin-
proteasome pathway has been observed (Bossola et al, 2001; Williams et al, 1999); this 
pathway has to our knowledge not been investigated in WAT in conjunction with 
cancer cachexia. Secretion of Zinc-α2-glycoprotein (ZAG) from human WAT is 
increased in cancer cachectic subjects (Mracek et al, 2011; Tisdale, 2009). ZAG is an 
abundant circulating protein that enhances the lipolytic effect of catecholamines on fat 
cells. It is produced by the host and by certain tumors. Given its lipid-mobilizing effect, 
ZAG may contribute to WAT atrophy associated with cancer cachexia in human 
beings. However, ZAG secretion from WAT increased significantly in obese subjects 
on a VLCD (Ryden et al, 2011). Thus, WAT-secreted ZAG correlates with nutritional 
status, i.e.catabolism,  in both cancer and nonmalignant conditions.  
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2 AIMS 
WAT is the organ most strongly affected by obesity and cachexia. We hypothesize that 
alterations in WAT function contribute to the negative metabolic consequences and 
disease outcome, respectively, of these two disorders. In this thesis we apply global 
transcriptome profiling to generate new hypothesis on molecules and pathways of 
relevance for WAT function. 
 
The specific aims are 
 
1) to search for differentially expressed genes in human omental and 
subcutaneous WAT  
 
2) to elucidate diet-regulated gene expression changes in subcutaneous WAT of 
obese women 
 
3) to establish whether different macronutrient content of food gives different 
gene expression changes in WAT 
 
4) to elucidate the role of Follistatin in WAT 
 
5) to study gene expression changes and gene regulation in WAT in cancer 
cachexia  
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 GENERAL COMMENTS CONCERNING SUBJECTS 
All studies were performed in humans. There are differences in the distribution of 
WAT depots and metabolism between human and rodent. The clinical relevance of 
studies in rodent WAT is therefore unclear.  
 
There are gender differences in WAT function (Wajchenberg, 2000). To get optimal 
power it is therefore advantageous to study one gender at a time. In studies of obesity in 
humans it is often easier to recruit women and therefore we have often focused on 
female WAT in our studies. However, for the Representational difference analysis 
(RDA) in study 1 we choose the individual with the largest visceral adipose area, not 
surprisingly a man. Sometimes we had to mix genders to get significant results. In the 
cancer cachexia project more men than women were included. We evaluated all 
patients scheduled for gastrointestinal cancer operation for four years at our hospital for 
inclusion into the study. For practical reasons, e.g. the WAT biopsies, it was not 
possible to recruit subjects from other hospitals. To get sufficiently large groups for 
analyses, we included both women and men in the analysis. In this project, we did not 
observe any gender differences in the analysis of the results. This could possibly in part 
be due to the age of the population, mean age was 65 years, and gender differences is 
most pronounced between premenopausal women compared to men. 
 
To further minimize confounders in our obesity studies, we tried to minimize variation 
in baseline BMI and age in studied cohorts. We limited the studies to healthy 
individuals except obesity and almost always excluded those with medication. We 
usually study Caucasians living in Stockholm to avoid the influence of ethnicity on 
metabolism. Ethnic differences in adipose gene expression in insulin resistant states 
have been described (Elbein et al, 2011).  
 
A body mass index (BMI) greater than 30 kg/m2 was used as a definition of obesity. In 
study 2 and 3, most subjects were recruited by advertisement. We do not know if obese 
subjects recruited this way differ from obese in the general population. 
 
In general, in our studies, sample size was calculated with the aim of getting some new 
interesting finding, i.e. identify some new genes that were differentially expressed 
between the compared clinical conditions. The aim was not to define the whole 
spectrum of WAT differentially regulated genes. Given the heterogeneity of obesity, as 
shown in recent genome scans (Speliotes et al, 2010), we expect there to be large 
variation in WAT gene expression within the obese population that require very large 
sample sizes to be defined. van Beek showed 2007 (van Beek et al, 2007) that the 
variation in gene expression between multiple WAT biopsies from the same individual 
and depot is small but the variation between individuals is considerable, also 
highlighting the importance of large sample size in human WAT studies. 
 
The hospital´s committee of ethics approved each study.  
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3.2  DESCRIPTION OF STUDY COHORTS  
Study 1: The obese subjects (7 males and 11 females) included were members of a 
subgroup of patients participating in a clinical trial of adjustable gastric banding 
(Thorne et al, 2002). From these subjects, it was possible to obtain adipose specimens 
from omental as well as subcutaneous WAT. We selected the subject that had the 
greatest ratio of intraabdominal to subcutaneous WAT for RDA. His proportion of 
visceral versus total WAT area was 53% (426 cm2 visceral WAT area, 352 cm2 
subcutaneous WAT area) and WHR was 1.10. To verify differential gene expression in 
other obese subjects, we used a pool of patient samples. We had to pool RNA since the 
microarray hybridizations at that time required more RNA than was available from 
each subject. WAT from 6 males and 11 females was used to prepare female and male 
visceral and subcutaneous RNA pools, respectively. If we had performed the study 
today, the modern methods which need less RNA would have permitted us to 
investigate all samples individually showing the inter individual variation which 
probably is considerable (van Beek et al, 2007).  
 
Study 2: This study was part of the European multicenter study termed Nutrient-Gene 
Interactions in Human Obesity-Implications for Dietary Guidelines (NUGENOB 
www.nugenob.org) within which the interaction between two hypoenergetic diets and 
genes was examined in 771 European patients. The present study was performed at the 
local center at Karolinska University Hospital, Huddinge, Sweden. 100 obese subjects 
(women and men) were recruited at the hospital and randomly assigned to either a low-
fat, high-carbohydrate hypoenergetic diet or a moderate-fat, moderate-carbohydrate 
hypoenergetic diet for 10 weeks. 
 
Dietary intervention: Energy intake during both diets was only moderately reduced, 
600 kcal/day less than the individually estimated energy requirement. The aimed 
macronutrient composition was for the low-fat diet 20–25% of total energy from fat, 
15% from protein and 60–65% from carbohydrate, and for the moderate-fat diet 40–
45% of total energy from fat, 15% from protein and 40–45% from carbohydrate. When 
the study was planned low fat diets were claimed to be superior to high fat diet in 
producing weight loss and possibly also for weight maintenance. It was thought that 
carbohydrates are more satiating than fat and that overeating might be more likely with 
a high-fat diet because of the higher energy density and greater sensory pleasure. 
Dietary composition might affect risk factors for CHD and T2D by altering blood lipids 
or insulin resistance, therefore these were monitored. Compliance with diet was 
evaluated by weighed-food records and was within or close to the target ranges. 
 
From the first 40 women out of the 100 subjects recruited at Huddinge, fine needle 
abdominal subcutaneous WAT biopsies were obtained before and after the diet period 
for investigations of WAT in relation to diet. We were able to isolate high quality RNA 
from WAT samples before and after intervention from 23 of the 40 women in order to 
perform global transcriptome profiling; n=10 of these women belonged to the low-fat, 
high-carbohydrate hypoenergetic diet and n=13 women to the moderate-fat, moderate-
carbohydrate hypoenergetic diet. This subgroup did not differ from the whole group in 
baseline clinical measurements.  
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Study 3: To study the role of Follistatin in WAT, four cohorts comprising 10-35 
subjects each were investigated. The sample sizes were chosen based on known pattern 
of expression of Follistatin mRNA in WAT in relation to obesity according to a 
microarray study (Dahlman et al, 2005). We took into account that microarray tends to 
squeeze the overall variation in expression of a gene. 
 
Study 4: All patients in Karolinska scheduled for gastrointestinal cancer operation 
between March 2004 and March 2008 (about 500 patients) were evaluated for the study 
and patients who (a) were fit in spite of their cancer, (b) had not received prior 
anticancer treatment, (c) did not have clinical evidence of gastrointestinal obstruction 
and (d) were willing to participate were included (n=53). The remaining ones were 
excluded due to severe illness, evidence of gastrointestinal obstruction, disinclination, 
communication problems and logistic reasons. Patients were divided into three groups 
based on diagnosis after surgery. One group had cancer cachexia (n=13), which was 
defined as gastrointestinal cancer with unintentional weight loss of >5% of the habitual 
weight during the previous three months or >10% unintentional weight loss during the 
previous six months (Agustsson et al, 2007). The primary location of cancer was 
pancreas (n=11), stomach (n=1) and colon (n=1). The second group (n=14) consisted of 
patients with gastrointestinal cancer who reported no important weight change during 
the last year. The localization of malignancy was pancreas (n=6), esophagus (n=1), 
stomach (n=1), colon (n=3), gall bladder (n=1) and liver (n=2). The remaining 26 
patients were excluded either because, although pre-diagnosed with gastrointestinal 
cancer, they did not have a malignancy according to final histological evaluations 
(n=8), or because we did not obtain adequate amounts of WAT for a complete 
investigation (at least 0.9 g). 
 
We used the method by Liu to determine the appropriate sample size for microarray 
experiments in the cachexia study (Liu & Hwang, 2007). Assuming that significant 
differences in gene expression between the two studied groups were defined with a 
false discovery rate (FDR) of 5%, the proportion of non-differentially expressed genes 
between groups was 0.95. Assuming a standard deviation for effect size of 1, a 
population consisting of two groups composed of 15 subjects each yields a power of 
approximately 90% to detect differentially expressed genes. This is close to the actual 
number of 13 cachectic and 14 weight stable patients used in the present analysis. 
 
We compared the changes in WAT gene expression associated with cachexia with 
changes in gene expression associated with obesity in two microarray studies reported 
elsewhere (Dahlman et al, 2005; Mutch et al, 2009). One study included Affymetrix 
HGU95Av2 expression profiles on 17 non-obese and 20 obese healthy Swedish women 
(Dahlman et al, 2005). The second study described Agilent 4x44K gene expression 
profiles in surgically-obtained subcutaneous adipose tissue biopsies from 9 obese and 
10 lean age-matched subjects (Mutch et al, 2009). Differences in gene expression 
between isolated adipocytes and stroma vascular cells were examined in subcutaneous 
WAT in another group of overweight women (n = 9), as previously described(Clement 
et al, 2004).  
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3.3 ADIPOSE SAMPLING  
All subjects were investigated in the morning after a night’s fast. This is important 
since changes in nutritional status has acute effect on WAT expression.(Clement et al, 
2004). Abdominal subcutaneous WAT biopsies were obtained by needle aspiration 
under local anesthesia as described earlier (Large et al, 1997). When both subcutaneous 
and omental WAT were studied we used biopsies obtained in conjunction with surgery. 
The WAT was taken from the surgical incision and omental WAT at start of surgery. 
None of the operated patients showed signs of general inflammation. Subcutaneous 
WAT samples obtained by needle and surgery were never included in the same 
comparison. WAT obtained by these two approaches are shown to differ slightly, the 
surgery biopsy containing more stroma vascular cells (Mutch et al, 2009). Fine needle 
biopsies are also shown to give higher variation of gene expression, possibly due to 
disruption and possible contamination of the tissue with blood (van Beek et al, 2007). 
Therefore we tried to rinse the WAT from blood prior to freezing. 
 
3.4 BODY COMPOSITION AND FAT DISTRIBUTION 
There are different methods to assess fat mass and adiposity in humans. Body mass 
index (BMI) and waist hip ratio (WHR) are common measures to describe if you are 
overweight and to appreciate fat distribution. BMI >18.5 and <25 and WHR <1 is 
considered normal for men. BMI >18.5 and <25 and WHR <0,8 are the normal values 
for women. Waist circumference is becoming more widespread as a measurement of 
visceral adiposity, where the International Diabetes Federation  recommends >94 cm 
for men and >80 cm for women as cutoffs for abdominal obesity (Alberti et al, 2009). 
Abdominal CT scan was used in study 1 to assess intra-abdominal and subcutaneous 
adipose areas at L4-L5. There is so far no clear recommendation of normal levels of 
WAT areas when assessed by CT, but international obesity and diabetes federations are 
aiming for it. Several earlier studies have found an increased cardiovascular disease risk 
when visceral fat area exceeds 100-130 cm2 (Wajchenberg, 2000). Higher levels of 
visceral WAT( >140 cm2 for males and >114 cm2 for women) were associated with 
greater prevalence of several clinical cardiovascular manifestations in individuals both 
with and without T2D in a study of 4144 individuals from 28 countries (Smith et al, 
2012). Modern CT techniques for fat mass evaluations measuring WAT areas 
volumetrically will probably increase accuracy further. Dual energy x-ray 
absorptiometry (DXA) can measure total fat and lean body mass. The radiation dose is 
much less than CT. The new software to evaluate visceral WAT area or volume by 
DXA was not available when our studies were performed. In study 4 body composition 
was estimated by bio-impedance using Quad Scan 4000 which estimates % body fat 
and lean body mass. MRI gives good quality measurements but so far the MRI 
equipment is expensive and often prioritized for other usage. 
 
3.5 ADIPOSE RNA PREPARATION 
In paper 1 subcutaneous and omental WAT from individual subjects were 
homogenized and total RNA was isolated using Trizol reagent. The quality was 
ascertained on denaturing agarose gels and concentration determined 
spectrophotometrically. For the verification of RDA results equal amounts of total 
RNA were mixed to generate female (n=11) and male (n=6) RNA pools.  
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In general it is difficult to isolate RNA from adipose tissue with high yield due to the 
high lipid content of the tissue. More recently, however, premanufactured kits that can 
be used to efficiently isolate RNA also from WAT have been developed. These kits 
simplify the laboratory work. In study 2 and study 3 frozen subcutaneous WAT from 
each subject was crushed under liquid nitrogen, and total RNA was prepared using the 
RNeasy mini kit (Quiagen, Hilden,Germany). In Study 4 we used the Nucleospin 
RNA11 kit (Macherey-Nagel, Duren, Germany).The advantage with Nucleospin is that 
it allows preparation of RNA and DNA in parallel from the same tissue piece. We used 
DNA preparation for quantification of mitochondrial DNA (mtDNA). RNA-
concentrations were measured spectrophotometrically to check for integrity and purity 
(A260/A280 ratio). The quality was confirmed by an Agilent 2100 Bioanalyzer, which 
uses a microfluidics-based chip for eletrophoresis and size separation . 
 
3.6 CDNA-RDA 
cDNA representational difference analysis (cDNA RDA) is a PCR-based subtractive 
enrichment procedure for the cloning of differentially expressed genes. During the 
90ies, before the era of microarrays, several PCR-based methods were developed to 
facilitate rapid and sensitive analysis of differential gene expression. Among these 
counted differential display, RNA fingerprinting by rapidly primed PCR, SAGE and 
RDA for cDNA. RDA was originally developed by Lisitsyn and coworkers (Lisitsyn & 
Wigler, 1993) for analysis of differences between closely related genomes, and further 
developed for cDNA-analysis by Hubank and Schatz (Hubank & Schatz, 1994). 
Compared to differential display, RDA minimizes the risk of isolating false positives. 
Also, it has the potential for analysis of differences in gene expression on different 
levels through modulation of driver:tester ratios (Odeberg et al, 2000). Thirdly, 
unwanted clones can be included in the driver, thereby inhibiting their amplification. 
Our RDA project was initiated before the era of global transcriptome analysis by 
microarray (Venter et al, 2001). We choose to use cDNA RDA to search for differences 
in omental versus subcutaneous WAT mRNA expression. With this method we hoped 
to get a non-hypothesis based screening method for identification of new genes 
involved in the complications of obesity and to isolate the expression differences 
between the two tissues. Below is a picture describing the procedure of RDA.  
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regulated networks (Schadt, 2009). We are moving from the search for a disease-
specific gene to the understanding of the biochemical and molecular functioning of a 
variety of genes whose disrupted interaction in complicated networks can lead to a 
disease state (Trachtenberg et al, 2012). Transcriptomics, the large scale measuring of 
gene expression, is one of important pieces to reach the goal of functional 
characterization.  
 
3.7.1 cDNA microarray  
The RDA-study was planned and performed before microarrays for inferring the global 
transcriptome were widespread commercially available. We set up our own cDNA 
array facility to verify the RDA-derived results using a new set of samples. In order to 
verify many clones, which is often the result of the RDA-procedure used in study 1, we 
amplified the RDA products by PCRamplification and then printed them on amino-
silane coated slides, where the amino-silane coat provides hydroxyl groups which 
allows the spotted cDNA to covalently bind the surface (Andersson et al, 2003)  
 
Spotted or printed microarrays are prepared by printing probes of oligonucleotides or 
cDNA, that is prepared from known, selected probes. The probes hybridize to cDNA or 
cRNA derived from experimental samples. For gene expression analysis, the 
transcriptome of the sample is analyzed through hybridization with the complementary 
probes present on the array. It is important to note that the query sample needs to be 
labeled to allow signal detection by scanning in confocal microscopy. A signal is 
detected when the target hybridizes to its corresponding probe sequence on the array. 
Labeling of RNA samples can be achieved through a reverse transcription reaction by 
direct incorporation of nucleotides linked to fluorochromes, typically Cy3 or Cy5. The 
resulting cDNA can then be hybridized to the array under stringent conditions. After 
incubation, the array is washed to remove any nonspecific hybridization and to reduce 
background signals. Laser confocal devices are next used to scan the arrays and acquire 
images and spot intensities. By measuring the amount of cDNA bound to each spot 
(fluorescence intensity) it is possible to determine expression of that particular gene. 
 
Printed arrays (cDNA and long oligo arrays) allow the contemporaneous hybridization 
of the two different samples, labeled with different fluorochromes, so that the test and 
control can be directly compared on the same slide. For this reason, printed arrays are 
also called “two-color arrays”. Direct comparison of the samples on the same array 
reduces artifacts due to uneven hybridization, local background differences, and slide-
to-slide variations; on the other hand, dye bias requires performing dye-swap replicates. 
Experimental design is important using two-color array, especially if you are not just 
comparing two situations like before and during treatment.  
 
Image analysis was performed as described in the RDA-study using Genepix Pro 
software. The cut-off for selection of upregulated and downregulated genes was set to 
1.5 due to earlier experience in our group confirming our cDNA-array results with RT-
q-PCR. 
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Another array platform is the Illumina array technology.  The Illumina process involves 
using standard oligonucleotide synthesis methods as is used for spotted long-
oligonucleotides arrays. However, on Illumina arrays the oligonucleotides are attached 
to microbeads which are then put onto microarrays using a random self-assembly 
mechanism. The probe selection and design procedure differs from Affymetrix and also 
the packaging. In the current packaging, multiple Illumina arrays are placed on the 
same physical substrate, meaning that hybridization and other steps are performed in a 
parallel manner. The Affymetrix arrays that we have used are processed separately. 
 
3.8 REAL-TIME QUANTITATIVE PCR 
For individual gene expression measurements, for example to confirm results from 
microarray studies, real-time quantitative PCR (RT-q-PCR) is the method most 
commonly used today (Lutfalla & Uze, 2006). First cDNA is reverse transcribed from 
sample RNA, and then gene-specific amplification by RT-q-PRC is performed.  With 
the use of fluorescent molecules, each cycle of replication in RT-q-PCR can be 
monitored by sensors. There are differerent approaches in real-time quantification. We 
have applied Taqman and SYBR Green technology. The Taqman technique uses a 
gene-specific probe which has a fluorophore on one end and a quencher on the other 
end. Close proximity of the fluorophore and quencher prevents signal emission. Upon 
amplification of the specific gene, the polymerase will digest the bound probe and the 
fluorophore will be detected by its specific wavelength. 
 
 An alternative and less costly method uses SYBR Green. SYBR Green is a molecule 
that binds to doublestranded DNA. During PCR amplification, doublestranded DNA is 
produced, and SYBR Green binds to it and can then be detected. Since SYBR Green 
binds to all doublestranded DNA there is a risk of false positives from primer dimers 
and unspecific products. This risk can be minimized by careful primer design, the use 
of dissociation curves, and the use of electrophoresis gels which should show one 
single amplified product. RT-q-PCR in this thesis uses mostly the SYBR Green 
technique but in study 2 and 3 some genes were analyzed with Taqman probes. We 
have purchased commercial Taqman-kits, and tried to choose kits covering all known 
splice variants of the gene. Concerning primer design we excluded repeat regions by 
Repeat masker and used the software Primer3 to design the primers. We used 
bioinformatics to check that the predicted amplicon covered exon-exon borders to 
avoid amplification of genomic DNA We also checked that primers did not cross-react 
with other genome sequences using BLAST search. 
 
To ensure that equal amounts of cDNAfrom different samples are compared , it is 
essential to determine mRNA levels of reference genes. These “housekeeping”-genes, 
are genes that are not affected by the conditions studied. Our use of reference genes has 
changed over time as we have learnt about new genes that display less variation 
between samples and experimental conditions. In study 2 we used GAPDH and in 
study 3 and 4 18S rRNA. After the completion of our studies Gabrielsson published a 
comparison of reference genes in WAT and found that LRP10 had the least variation 
(Gabrielsson et al, 2005). The optimal solution is probably to include several reference 
genes. Different genes might be suitable in different situations depending on 
experimental setup. A direct comparative method was used for data analysis, 
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 i.e. 2(Ct target gene calibrator − Ct target gene sample)/2(Ct 18S calibrator − Ct 18S sample). As an 
alternative a standard curve can be used to compare mRNA levels between samples. 
 
3.9 BIOINFORMATICS 
High throughput omics technologies generate massive amounts of data that require 
extensive data analysis, as well as data storage. In the last decade numerous new 
software have been developed and new possibilities arise as computers and software 
can cope with increasing amounts of data at a higher speed (Trachtenberg et al, 2012).  
 
Microarray data analysis starts with normalization of raw signals on the arrays, 
whereafter signals from different arrays can be compared. After microarray 
normalization, the raw data is further analyzed in order to identify genes differentially 
expressed between groups.  For microarrays this analysis involves the simultaneous 
analysis of thousands of genes. With a nominal p value of 0.05 there will therefore be 
many false positive. Different approaches to adjust significance thresholds have been 
proposed. In study 2 and 4 we used the Significance Analysis of Microarrays (SAM) 
(Tusher et al, 2001) statistical program especially designed for microarray analysis. 
SAM adjusts for the multiple comparisons caused by the presence of thousands of 
genes on the microarrays. A score is assigned to each transcript based on its change in 
gene transcription in relation to the standard deviation of replicated measurements for 
that particular gene. SAM estimates the false discovery rate (FDR), which is the 
percentage of genes expected to be wrongly identified as differentially expressed. Each 
gene is assigned a q-value that indicates the minimum FDR at which the differential 
expression of the gene is called significant. SAM was used in our array studies and 
gave lists of differently expressed genes. There are additional approaches to identify 
differentially expressed genes, such as T test with Benjamini-Hochberg adjustment. 
However, our experience is that SAM is efficient to detect differentially expressed 
genes. Furthermore, we can confirm results obtained with SAM by RT- q-PCR, even 
with fold change as small as 1.2, and we therefore continue to use SAM. 
 
To further understand the gene changes we used several software that aim at 
categorizing the genes in pathways and gene ontology categories. I will briefly mention 
some of them below. Many more software are available. However, since the software 
we have used produce similar results, we do not think the use of additional ones will 
improve our interpretation of results. Rather it is our belief that the limiting factor in 
pathway analysis is the annotation of genes, and the complex physiology. That is, too 
little is known about the function of many genes to allow them to be grouped into more 
detailed pathways. 
 
FunNet integrates experimental gene expression data and knowledge about transcript´s 
biological roles, available in genomic annotation systems (Prifti et al, 2008). FunNet 
performs a functional profiling of gene expression data to identify a set of significant 
(i.e. overrepresented) biological themes characterizing the analyzed transcripts, i.e. 
cellular processes, pathways, or molecular functions in which the analyzed transcripts 
are involved. Then, based on the results of the functional analysis, a two-layer 
abstraction model is built to integrate the two types of transcriptional information: 
expression levels and transcripts’ biological roles. This model is further used to derive a 
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measure of proximity between significant biological themes based on the similarity of 
the expression profiles of their annotated transcripts. In the end, themes demonstrating 
a significant relationship in the transcriptional expression space are associated to build 
transcriptional modules. FunNet relies on genomic annotations provided by the Gene 
Ontology consortium and the Kyoto Encyclopedia of Genes and Genomes. 
 
Gene Ontology Tree Machine (Zhang et al, 2004) is a web-based platform for 
interpreting sets of interesting genes using Gene Ontology hierarchies. A tree-like 
structure is created to illustrate changes in expression of Gene Ontologies. Statistical 
analysis helps users to identify the most important Gene Ontology categories from the 
input gene sets and suggests biological areas that warrant further study. We have based 
the input gene list on genes that are differentially expressed between groups according 
to SAM. 
 
Gene Set Enrichment Analysis (GSEA) (Subramanian et al, 2005) is a computational 
method that determines whether an a priori defined set of genes shows statistically 
significant, concordant differences between two biological states even though the 
individual genes in the gene sets may not be significantly differentially expressed 
between groups. GSEA cannot be used for paired analysis.  
 
SIMCA-P (Umetrics AB, Umea, Sweden) is a software used in multivariate analysis to 
get an exploratory overview of your data including assessment of the quality of your 
samples. Principal component analysis evaluates the principal components of a data set.  
Partial least square analysis can optimize the separation between groups. We have used 
SIMCA to get an overview of our datasets, before proceeding to other analysis. 
 
An unbiased approach to detect functional connection between genes is cluster analysis 
that detects groups of genes that display similar expression between samples. We have 
successfully applied cluster analysis on our microarray results. However, genes in 
detected coexpressed clusters did not display any obvious functional connection. We 
therefore do not report the results of this analysis. 
 
3.10 PROTEIN DETECTION 
Enzyme-linked immunoassay was used to examine in vitro secretion of Follistatin in 
study 3. Western blot was used for protein measurements in study 3 and 4. Western blot 
in study 3 was used to confirm the size of the detected protein. 
 
3.11 ISOLATION OF WHITE ADIPOSE TISSUE CELLS 
In study 2-4 WAT pieces immediately underwent collagenase treatment followed by 
determination of fat cell volume and weight of isolated fat cells as described (Large et 
al, 1997)( Rodbell & Krishna, 1974). Lipid content was assessed by AdipoRed assay 
reagent. AdipoRed is a Nile Red fluorescent reagent that enables quantification of 
intracellular lipid droplets.  
 
The different cell types of the SVF were separated with antibody coupled microbeads 
and subsequently identified by fluorescence activated cell sorter analysis (Curat et al, 
2004; Sengenes et al, 2005): adipocytes, blood capillary endothelial cells, progenitor 
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cells, macrophages, lymphatic and blood vessel endothelial cells, and a fraction with 
lymphocytes  and mast cells.  
 
3.12 IN VITRO ADIPOGENIC DIFFERENTIATION 
The non-adipose cells harvested from the SVF of WAT that was obtained after 
collagenase treatment was used for in vitro differentiation of preadipocytes as described 
(van Harmelen et al, 2002)(Hauner et al, 1995).  
 
In study 3 we also used another primary progenitor cell type; human bone marrow-
derived mesenchymal stem cells (hMSC). For adipogenesis experiments these cells 
were grown to 100% confluence and then induced with adipogenic medium. They were 
treated according to the specific experiment and cells were analyzed for lipid content, 
differentiation and RNA expression. Different types of human fat cell cultures display 
some differences in phenotype, primarily in gene expression. Which cell type that is 
used in different projects depends on which is the most appropriate fat cell type for the 
specific experiment, but also on the availability of specific fat cell types in different 
laboratories. The stem cell derived fat cells may better mimic the primary phenotypes 
of adipocytes, whereas mature adipocytes isolated from donors may display secondary 
changes due to obesity etc. 
 
   23 
4 RESULTS AND DISCUSSION 
In this section I will summarize and discuss on the results from the individual papers, 
All details about the results, p-values, graphs and tables can be found in Papers I-IV.  
 
4.1 PAPER 1 
There are since long ago known structural and functional differences between 
subcutaneous and visceral WAT (Wajchenberg, 2000). It is still unknown whether 
molecular changes in visceral or omental WAT can explain the increased mortality and 
risk for T2D and cardiovascular complications associated with visceral WAT that many 
prospective studies have shown (Wajchenberg et al, 2009). This study was planned and 
initiated in the late 90s before whole genome microarray technology was available. 
cDNA RDA was applied to search for and clone differences between omental and 
subcutaneous WAT mRNA. With this method we hoped to get a non-hypothesis based 
screening method for identification of new obesity genes and to isolate the expression 
differences between the two tissues.  
 
We chose to clone the differentially expressed RNA between subcutaneous and 
omental WAT from one individual; a man with an extreme phenotype of prominent 
visceral obesity. His proportion of visceral adipose was 53% of total adipose mass, 
compared to the normal amount of 10-20% in men. His visceral area was enormous, 
426 cm2 and exceeded the subcutaneous area (352 cm2). A recent European study of 
visceral adipose area in 28 countries (Smith et al, 2012) found that areas exceeding 140 
cm2 in men predicted increased CVD-risk and T2D. Our patient’s WHR was 1,10 and 
BMI 39 km/m2. Since it is shown that each cm (measured by ultrasound) increase of 
intraabdominal WAT increases the risk for CVD (Kanhai et al, 2011) this man ought to 
be a high-risk individual. There are of course drawbacks by our approach of using a 
single patient as material for cloning. We know that there are considerable inter-
individual variations in WAT gene expression (van Beek et al, 2007; Zhang et al, 2007) 
and by investigating only one individual, expression differences that might exist in 
other subjects and not in our subject will not be found. Since our patient material of 
extremely abdominally obese individuals was limited we could not use a group of 
abdominally obese subjects but chose instead to clone only the most extreme subject 
and then to verify his expression differences in another group of obese subjects.  
 
After cloning the mRNA differences between the patient´s subcutaneous and omental 
WAT, sequencing 768 clones, and excluding redundant clones, resulted in the 44 
unique gene sequences presented in Table 2 in the paper. Many of these genes are 
previously been shown to be expressed in WAT, e.g. Adipsin, Properdin, Serum 
Amyloid A, Secreted Protein, Acidic and Rich in Cysteine (SPARC), Phospholipid 
transfer protein (PLPT) and several ribosomal proteins. We have compared the 44 gene 
sequences with genes differentially expressed between subcutaneous and visceral WAT 
in lean, obese and T2D-patients in a more recent study by Dahlman et al (Dahlman et 
al, 2006). 23 genes were also found on the wholegenome microarray used by Dahlman 
and 17 of these were differentially regulated. Of these eight were ribosomal proteins 
which all were overexpressed in omental WAT. SPARC was more common in 
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subcutaneous WAT as reported earlier and Annexin A8 overexpressed by omental 
adipose. S100A6 was not differentially regulated on the microarray.  
 
In differential cloning procedures, one may pick up false positives, i.e. genes that are 
not differentially expressed. In this study we choose to evaluate this and simultaneously 
test if the patient’s expression differences were valid in other obese individuals by 
testing a new set of male patients. In addition, we attempted to search for sex 
differences in expression by analyzing a group of obese females. To enable a rapid 
screening, we used cDNA microarray technology. The 44 RDA clones were spotted in 
triplicate onto glass slides and hybridized to fluorescently labeled cDNA from the 
above-mentioned male and female RNA pools. 16 (36%) of the cloned genes were 
detected in the pools of male or female subcutaneous or omental RNA. Four clones 
were differentially expressed in female pool, and five in the male pool between 
subcutaneous and visceral WAT. The relatively low frequency of detected clones could 
indicate biological differences between the RDA patient and the pools but we must also 
consider methodological explanations. The cDNA-technology has limited sensitivity. 
In our case, we used RDA clones which had lengths between 75 and 500 bp, which 
differs from commercial cDNAarrays. Using the same approach as ours, Boeuf et al 
(Boeuf et al, 2001) confirmed differential expression for 30% of obtained RDA-clones 
by microarray validation. Concerning biological differences the RDA-patient with 
prominent metabolic syndrome differs compared to the pools where the patients were 
extremely obese but with relatively modest clinical characteristics. Recent studies show 
that the gene expression differences are larger with worsening metabolic disease 
(Klimcakova et al, 2011). 
 
The choice to pool RNA to a female and male pool can be criticized. Our cDNA-array 
technology demanded quite large RNA-amounts and we had to either pool individual 
RNAs or to amplify them. Since the experience with RNA amplification at that time 
was limited we chose not to amplify. Because of inter individual differences in gene 
expression pooling probably decreases the chance of finding differentially expressed 
genes. Repeating the study today I would have chosen to measure individual samples.  
 
Three genes were found differentially regulated with higher expression in subcutaneous 
WAT in our male and female pool, i.e. Adipsin, Calcyclin, and a PAC clone. Adipsin 
and Properdin, which was cloned in the RDA but not proven to be differentially 
expressed in the pools, are components of the alternative complement system. High 
expression of complement components in omental WAT of obese men were described 
by Gabrielsson (Gabrielsson et al, 2003) who also found that Adipsin was 
overexpressed in subcutaneous WAT in line with our result. In addition to their roles in 
innate immunity, a dual role for complement has been suggested in adipocyte biology 
where Properdin is proposed to act as a switch between immune versus metabolic 
drives (Gauvreau et al, 2012). It is present in adipocyte cell surface membranes and 
may interfere with fatty acid uptake and esterification. Calcyclin, or S100A6 is a 
calcium binding protein whose expression is upregulated in proliferating and 
differentiating cells. We found an overexpression in subcutaneous WAT. This protein 
may function in stimulation of Ca2+-dependent insulin release. Its serum levels 
correlates with advanced cardiovascular disease in rats (Cai et al, 2011). There is an 
increasing interest in the adipokines as mediators in atherosclerosis (Zhang et al, 2010) 
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and S100A6 could be a candidate. The release from fat cells is stimulated by FFA and 
this release can be inhibited by insulin. A recent study by Cai (Cai et al, 2011) showed 
an association between serum levels of among other S100-proteins S100A6 and acute 
coronary syndrome.  
 
We cloned several ESTs of unknown function but only one of them fulfilled our criteria 
for differential expression and interestingly only in the male pool where it was more 
expressed in subcutaneous WAT. The gene product codes for a voltage-dependent 
calcium channel subunit alpha-2/delta-3 precursor. The classical roles of α2δ proteins 
are as accessory calcium channel subunits, enhancing channel trafficking (Bauer et al, 
2010). We do not know the function of this subunit in male WAT. It is interesting to 
speculate about gender specific differences which so far are not widely investigated in 
WAT gene expression. Wolfs (Wolfs et al, 2010) found a module of gender related 
genes that were differentially expressed but the individual genes were not reported. 
 
Two genes were overexpressed in omental WAT of both the male and female pool, 
PLPT and RAS, involved in lipid metabolism and signal transduction. PLPT transfers 
phospholipids from TAG-rich lipoproteins to high density lipoprotein (HDL). In 
addition to regulating the size of HDL particles, this protein may be involved in 
maintenance of efficient cellular cholesterol efflux by local expression in the vascular 
wall. The earlier plausible positive antiatherogenic role has recently been challenged by 
another picture: systemic PLTP act as a pro-atherogenic factor by increasing the 
production of apolipoprotein B-containing lipoproteins to decrease their antioxidative 
protection and to trigger inflammation. PLPT and related Cholesteryl transfer protein 
are secreted proteins and WAT is an important contributor to the systemic pools of 
these two proteins. PLTP activity and mass have been reported to be abnormally 
elevated in T2D and insulin-resistant states, and this elevation is frequently associated 
with hypertriglyceridemia and obesity. Haplotypes in the PLPT gene are associated 
with obesity-related phenotypes as shown by the the Québec Family Study (Bosse et al, 
2005).The RAS gene encodes a member of the Rho family of small GTPases which 
function as molecular switches in signal transduction cascades. Rho proteins promote 
reorganization of the actin cytoskeleton and regulate cell shape, attachment, and 
motility. Its expression is widespread and e.g. fibroblasts and endothelial cells express 
RAS. We found RAS expression to be higher in omental than subcutaneous WAT 
which could be due to a higher vascular density and endothelial cell abundance in 
omental WAT as described by Villaret (Villaret et al, 2010). 
 
There are some clones obtained by the RDA that were not found in the other subjects 
but that deserve mentioning because of biological interest. The cloning of SPARC from 
our abdominally obese man is interesting since it has gained interest as a plausible key 
player in obesity related complications (Kos & Wilding, 2010). SPARC was originally 
found in bone as Osteonectin, is expressed ubiquitously, but predominantly in 
adipocytes. Others have shown higher expression in subcutaneous compared to omental 
WAT (Vohl et al, 2004) (Klimcakova et al, 2011; van Beek et al, 2007) and recently 
also in larger adipocytes (Kos et al, 2009).  As a regulator of extracellular matrix, 
SPARC contributes to WAT fibrosis. Fibrosis of subcutaneous WAT may restrict 
accumulation of TAGs, which are therefore deposited as ectopic lipids in other tissues 
such as liver or muscle, and may predispose to insulin resistance in these organs. The 
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Comparing subcutaneous and omental WAT we found overexpression of genes dealing 
with GO-categories complement activation, protein biosynthesis and koagulation in 
omental adipose and lipid metabolism, transcription, energy pathways and phosphate 
transport in subcutaneous WAT. A larger number of genes displayed significant 
differences in expression between patient groups in the omental than in subcutaneous 
WAT. We have compared the results from these microarrays with the cloned genes 
from the RDA-study and found that 23 of the 44 RDA-clones were expressed on the 
whole genome microarray and 17 of these were differentially expressed between the 
WAT depots. Of these eight were ribosomal proteins which were all overexpressed in 
omental WAT. SPARC was verified as significantly higher expressed in subcutaneous 
WAT.  
 
In another study, Vohl performed wholegenome arrays of visceral and subcutaneous 
adipose in 10 obese men (Vohl et al, 2004). 131 genes were higher expressed in 
subcutaneous WAT and 216 in visceral WAT. Genes from the CEBPs and Wnt 
signaling pathways were higher expressed in omental fat and HOX genes in 
subcutaneous WAT, which may suggest differences in differentiation and adipogenic 
capacities. Reanalyzing these arrays Zhang (Zhang et al, 2007) measured 
interindividual variation between depots. More than 90% of clones showed a 
coefficient of variation of lower than 23,6 and 21,7% in omental and subcutaneous 
WAT. Among the highly regulated genes, 18 transcripts in subcutaneous WAT were 
involved in lipid metabolism and 28 transcripts in omental WAT were involved in cell 
death.  
 
An impressive study by Wolfs et al (Wolfs et al, 2010) performed whole genome arrays 
on subcutaneous and omental WAT from 75 massively obese individuals. The 
individuals were by blood parameters and BMI categorized as healthy obese, T2D, 
Nonalcoholic steatohepatitis (NASH)-patients and individuals with both NASH and 
T2D. They could show that 1344 genes were significantly upregulated in subcutaneous 
WAT, of these 609 with more than 1.5 fold change. 1246 genes were significantly 
overexpressed in omental WAT, and 909 more than 1.5 fold increased. A large number 
of genes had more than 10-fold higher expression in omental WAT. These genes were 
involved in signal transduction, cell adhesion, cell communication and developmental 
processes. Only 20 genes were >10-fold overexpressed in subcutaneous WAT. They 
were highly enriched in homeobox transcription factors. Groups of co-expressed genes 
were identified that correlated with lipid and glucose metabolism parameters; they were 
enriched with immune genes. 
  
In a recent study by Klimcakova (Klimcakova et al, 2011) whole genome gene 
expression arrays were used to investigate genes differentially expressed between 
subcutaneous and visceral WAT in 24 subjects with differing degree of obesity and 
metabolic syndrome. The depots were compared and also correlated with degree of 
obesity, visceral fat accumulation, insulin resistance and metabolic syndrome. 
Comparing visceral and subcutaneous gene expression identified 492 genes with higher 
expression in subcutaneous WAT and 560 genes with omental overexpression. The 
increase in adiposity and the worsening of metabolic status were associated with a 
coordinated down-regulation of metabolism-related and an up-regulation of immune 
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response-related gene expression. Molecular adaptations in subcutaneous WAT proved 
as discriminating as those in visceral WAT in differing lean from metabolic syndrome.  
 
Summarizing these large microarray studies it is evident that there are large expression 
differences between omental and subcutaneous WAT. Omental WAT seems to have 
more differentially expressed genes in relation to adiposity. Our RDA study 
underestimated the changes in gene expression between fat depots for several reasons. 
The cDNA RDA methodology do not pick up all differentially expressed changes. 
During the cDNA-RDA-procedure, lack of Sau 3A1 restriction sites in the mRNA 
might generate less than 100% coverage in the representations. Large representated 
fragments may not be efficiently amplified by PCR. We found 44 clones and would 
probably have found some more if more clones had been sequenced. Importantly, most 
of our cloned differentially expressed genes are verified in the large microarray studies 
(analysis not shown). The studies by Klimcacova and Wolfs clearly shows that 
expression changes between the subcutaneous and visceral WAT depots are more 
pronounced in subjects with severe metabolic syndrome and /or T2D than in the 
healthy obese. This encourages us to think that expression changes between these 
depots can guide us to find the metabolic changes leading to these diseases.  
 
4.2 PAPER 2 
The aim of paper 2 was to define dietary effects on WAT gene expression and to search 
for gene expression differences due to macronutrient composition. Genes and gene 
pathways responsive to dietary treatment and energy restriction may contribute to the 
development of obesity complications. 
 
NUGENOB 
The study was part of a European cooperation project called NUGENOB. 771 patients 
from eight European countries were randomized to either of two hypocaloric diets with 
different fat/carbohydrate ratios. The main clinical results were reported 2006 (Petersen 
et al, 2006). The low-fat diet produced similar mean weight loss as the moderate-fat 
diet, but resulted in more subjects losing >10% of initial body weight and fewer 
dropouts. Both diets produced favorable changes in fasting blood lipids, insulin and 
glucose.  
 
The clinical results have subsequently been confirmed. One of the larger studies 
comparing diets in 811 patients was performed by Sachs 2009 (Sacks, 2009) and 
showed consistent with our study a modest weight reduction, which was the same for 
all diets. Regardless of dietary composition the weight loss improved blood parameters 
and insulin resistance similarly. The study included the same diet composition as ours, 
but also two other diets, i.e. low carbohydrate and high protein diets. 
 
Our study within the NUGENOB consortium focused on WAT gene expression in 
relation to diet. We expected rather small changes in gene expression because of;  
 
• The mild energy restriction (aim -600 kcal/day) which according to the dietary 
registrations in our group of patients was even less, -500 kcal/day. 
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• The relatively long time period, 10 weeks, where the body might have adapted 
to the hypocaloric situation. 
• Differences in diet compositions was rather small and not far from our 
Swedish nutrition recommendations. 
 
In our subgroup of patients the total amount of calories from fat during the intervention 
was significantly different from baseline and was within the targeted 40–45 E% in the 
moderate-fat diet group (42+/-3 E%) and close to the targeted 20–25 E% in the low-fat 
diet group (28+/-4 E%). The reduction in energy intake was almost identical in the two 
groups (-556 vs  503 kcal/day).There was a marked difference in the percentage of total 
calories from carbohydrate and fat between the groups and also in the amount of dietary 
fiber. The percentage of total calories from protein also differed somewhat between the 
groups. The reported intake for the moderate- and low-fat diets, respectively, were for 
carbohydrates: 40 vs. 51  E%; dietary fiber: 13 vs 19 g/day; and protein: 19 vs. 21 E%.   
 
The decrease in body weight was 7,5% in both groups. Fat cell volume decreased and 
insulin sensitivity increased with weight reduction. We found no significant differences 
between the diet groups in fat cell volume, plasma insulin and glucose. Protein 
secretion in these patients were measured and reported by Arvidsson (Arvidsson et al, 
2004) and showed no differences between diets. The secretion rate of Leptin decreased 
by approximately 40%, as did that of TNF-alpha. Interleukin 6 and -8 decreased by 25-
30%, whereas the secretion of Plasminogen activator inhibitor 1 (PAI-1) and 
Adiponectin did not show any changes. PAI-1 levels in plasma increased, probably 
indicating that other sources such as liver or endothelial cells produced more PAI-1 in 
response to energy restriction. As expected S-Leptin decreased. 
 
Our global transcriptome analysis showed that 3746 of the 8500 genes represented on 
the microarray were expressed in WAT of more than half of the patients.  Of these, 
expression of 96 genes, that is 2.5%, was significantly changed by the intervention with 
hypocaloric diet. Fold change (expression after diet divided by before diet) among 
these genes varied between 1.10 and 1.46 for upregulated genes, and between 0.35 and 
0.90 for down-regulated genes, respectively. The pattern of response was almost 
identical between the two diets.  
 
Our study was one of the first to use microarray to study effects of diet on gene 
expression in WAT. A few other microarray studies on dietary impact on subcutaneous 
WAT gene expression have been published (Capel et al, 2009; Capel et al, 2008; 
Clement et al, 2004; Marquez-Quinones et al, 2010; Rizkalla et al, 2012) and our 
finding that there are no major macronutrient effects on WAT gene expression is still 
predominant. It is the energy restriction or decreased fat mass that induces WAT gene 
expression changes.  
 
Two other studies have examined WAT gene expression in the NUGENOB study. 
Viguerie performed RT-q-PCR on selected genes in two groups of 25 women each, 
(none overlapping with patients in our study) (Viguerie et al, 2005). 38 genes were 
studied. None of the genes was differentially regulated according to fat or carbohydrate 
content of diet. 10 genes were regulated by caloric restriction. Consistent with our data 
Viguerie showed a downregulation of genes involved in lipid metabolism. Only two of 
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the genes regulated by energy restriction in our study overlapped with the ones 
measured by Viguerie et al, FASN and CIDEA, which were not regulated by diet in 
their study. The discrepancy could depend on different genetic and cultural 
background, limited power, or on different probes for mRNA detection. 
 
Also part of the NUGENOB study Capel et al (Capel et al, 2008) performed global 
transcriptome profiling by microarrays on 47 women on the NUGENOB study diet. 
None of the women overlapped with our group. Concerning the method, unlike us 
Capel used RNA amplification before cDNA synthesis, and hybridized to cDNA arrays 
with 24469 Unigene clusters. We used Affymetrix oligonucleotide arrays with 8793 
genes, Our arrays did not cover as many transcripts as the ones used by Capel so we 
cannot expect to find as many differentially expressed genes or pathways. The two 
different microarray platforms might also give different results due to different 
principles in array design. The cDNA technology with longer clones might have 
different specificity.  
 
In accordance with our results, Capel et al showed that the majority of genes were 
downregulated by diet. Fatty acid metabolism was one of the downregulated pathways 
and Stearoyl-CoA desaturase 1 (SCD-1) was one of the most downregulated genes. 
Capel also observed a decrease in genes regulating triacylglyceride storage capacity, 
carbohydrate metabolism, electron transport, fatty acid and steroid metabolism.  
Interestingly, using two gene classification programs combined with the array results, 
and RT-q-PCR on a larger group of patients they could show five genes with 
differential expression between the two diets. Sirtuin 3 (SIRT3), Fatty acid binding 
protein 4 (FABP4) and the Glucocorticoid hormone receptor NR3C1 were among the 
genes that increased by the moderate fat diet. NR3C1 expression correlated with total 
and low-density lipoprotein cholesterol. Probably the considerably larger cohort with 
48 patients for the array analysis and 96 patients for RT-q-PCR analysis contributed to 
the more extended findings by Capel as compared to our results.  
 
Other dietary intervention studies applying WAT global transcriptome profiling 
When interpreting our results in NUGENOB it is important to remember that energy 
restriction and weight reduction may regulate mRNA levels via different mechanisms. 
An acute negative energy balance upregulates certain pathways whereas the same 
pathways can be unchanged or even downregulated after longer moderately 
hypocaloric diet. This is illustrated in the study by Capel et al (Capel et al, 2009). They 
measured insulin sensitivity by glucose disposal rate (GDR), and global transcriptome 
WAT gene expression profiles before and after 1 month of VLCD diet and again after a 
4 month weight maintenance program. During VLCD clusters of genes were associated 
with GDR. Of interest and in total agreement with our results, the genes associated with 
synthesis of unsaturated fatty acids were downregulated by VLCD and associated with 
changes in GDR. Furthermore, CIDEA, which was the most upregulated gene in our 
study, was on their list of gene predictors of insulin sensitivity using partial least square 
regression analysis.  
 
Overall the changes in adipose gene expression in our study was modest which is in 
accordance with other array-studies on human WAT in relation to hypocaloric diet e.g. 
Kohlemainen (Kolehmainen et al, 2008) found fold changes ranging between 0.67 and 
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1.68, which is very close to our 0.35-1.46. Kohlemainen performed a comparison of 
WAT gene expression before and after a 33 week dietary intervention program, where 
the first 12 weeks were moderate energy restriction which was followed by a weight 
maintenance phase. The weight reduction was comparable to our study. Weight loss or 
a lower fat mass resulted in decreased expression in a small subset of the measured 
genes. i.e. 105 of the approximately 22.000 annotated genes on the array. Pathway 
analysis revealed mainly changes in genes related to extracellular matrix and cell death. 
These pathways, which were not observed in our study, could be due to Kolehmainen 
investigating WAT expression in the weight maintenance phase when the metabolic 
situation is in steady state and changes mostly depend on the actual weight, while we 
were looking at a catabolic state with ongoing moderate energy restriction. 
 
The DiOGenes program is a randomized, controlled dietary intervention study 
investigating the effects of dietary protein and glycaemic index on weight (re)gain, and 
metabolic and cardiovascular risk factors in obese and overweight families in eight 
European centres (Larsen et al, 2010). After an initial eight week LCD, the weight-
reduced obese subjects were assigned to ad libitum low-fat diets with different protein 
amounts and glycemic index. One report from the Diogenes trial (Marquez-Quinones et 
al, 2010) investigated subcutaneous WAT mRNA to identify gene biomarkers of 
weight control during the weight maintenance follow-up period. The authors concluded 
that the main differences in WAT gene expression were due to weight variations rather 
than to differences in dietary macronutrient composition. There was no gene expression 
patterns associated with macronutrient diet composition.  
 
It could be that the macronutrient impact on WAT gene expression is overrun by the 
influence of reduced fat mass in intervention studies which in parallel studies 
hypocaloric diet. Normocaloric studies, comparing different diets, are therefore of 
interest. Kallio (Kallio et al, 2007) evaluated for the FUNGENUT study the effect of 
two different normocaloric carbohydrate diets in patients with metabolic syndrome. 
Kallio could show that a low GI diet composed of rye, pasta and wholegrain cereals 
could improve the insulinogenic index and downregulate genes linked to insulin 
signaling and apoptosis in WAT, whereas the oat, wheat and potato-diet upregulated 
genes related to stress, cytokine-chemokine-mediated immunity and interleukin 
pathways.  
 
The association between gene expression changes in WAT and modification of 
adipocyte size was explored recently by Rizkalla (Rizkalla et al, 2012) comparing a low 
calorie conventional diet with a  low calorie diet with low GI and more protein and 
soluble fiber (LC-P-LGI). Rizkalla could show that the diets were similarly effective in 
reducing weight in moderately obese participants. Like in our NUGENOB study, that 
global WAT gene expression changes did not differ between diets. Unexpectedly there 
was a greater reduction in adipocyte size after the LC-P-LGI diet than after the low 
calorie conventional diet. The reduction in adipocyte size correlated with several 
parameters of importance for CHD-risk. Smaller adipocytes correlated with some WAT 
gene expression pathways, i.e. inhibition of adipogenesis, cell migration, adhesion, and 
angiogenesis, but increased expression of apoptosis genes. Altogether they could show 
a WAT gene expression pattern that correlated with adipocyte diameter, which 
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stimulates further studies concerning local remodeling changes in human adipose tissue 
and their association with diet and systemic improvement of metabolic variables. 
 
It is evident from our, Viguerie’s and Capel’s WAT gene expression studies on the 
NUGENOB cohort that 10 weeks of moderate energy restriction reducing weight 7-8 
kg is not enough to reduce inflammatory genes in adipose. Clement who studied a 
cohort of women before and after 4 weeks of VLCD described the modulation of 
several inflammatory genes induced by energy restriction When comparing WAT gene 
expression studies we should remember that all WAT samples from the above 
mentioned diet studies were obtained by needle biopsy, which poorly aspirates the 
fibrotic fraction of subcutaneous WAT, in turn resulting in an underrepresentation of 
the SVF (Mutch et al, 2009) . Therefore, gene expression in WAT in our study reflects 
mostly changes in adipocytes and to a lesser extent those in the SVF. 
 
SCD1 and CIDEA 
One of the most pronounced gene-nutrient interactions in our study was the 
downregulation of Stearoyl-CoA desaturase 1 (SCD1). SCD1 is a delta-9 fatty acid 
desaturase that converts saturated fatty acids (SFA) into monounsaturated fatty acids 
(MUFA). This activity is elevated by dietary carbohydrates (Flowers & Ntambi, 2009). 
Parallel activation of de novo lipogenesis and Stearoyl-CoA desaturase activity is 
shown in humans after three days of high-carbohydrate feeding (Chong et al, 2008). 
Thus, because SCD1 is the rate limiting step in the conversion of MUFAs, it is 
important in the regulation of the endogenous SFA pool caused by diet and de novo 
lipogenesis (Flowers, 2009). Elevated SCD1 activity within adipose tissue is closely 
coupled to the development of insulin resistance in humans (Sjogren et al, 2008). 
According to experimental studies, Scd-1 appears to play an important role in 
maintaining a balance in lipid profiles that, when deregulated, can contribute to 
inflammation, atherosclerosis, hypertriglyceridemia, and metabolic syndrome (Merino 
et al, 2010). It is thus possible that the reduced SCD1 expression in our patients is 
related to the improved insulin resistance.  
 
Our NUGENOB study, showing upregulation of CIDEA after energy restriction, evoke 
the interest for CIDEA in humans. Before our study, CIDEA was known as an 
apoptosis gene, and a mouse knockout model showed that mice deficient in CIDEA 
exhibited a lean phenotype. A study from our group (Nordstrom et al, 2005) extended 
the knowledge of human CIDEA expression by showing that CIDEA expression was 
decreased twofold in obese humans and normalized after weight reduction. This was 
later confirmed by others (Gummesson et al, 2007). Nordstrom showed that low WAT 
CIDEA expression was associated with several features of the metabolic syndrome. 
Human adipocyte depletion of CIDEA by RNA interference stimulated lipolysis and 
increased TNF-alpha secretion by a posttranscriptional effect. Recent studies show that 
CIDEA and other lipid droplet proteins define a highly regulated pathway of 
triacylglyceride deposition in human WAT. CIDEA colocalizes around lipid droplets 
(Christianson et al, 2010) with Perilipin, a regulator of lipolysis. Failure of this pathway 
results in ectopic lipid accumulation, insulin resistance, and is associated comorbidities 
in humans (Puri et al, 2008). 
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There are several limitations to our study. First of all, we studied no more than around 
8500 genes and the investigated group of patients was quite small. Since our study was 
one of the first microarray studies of diet-regulated WAT-changes we had limited 
information of the expected size of gene expression effects. Furthermore, the 
simultaneous analysis of hypocaloric diets and diets differing in macronutrient content 
may have limited the opportunity to identify the influence of macronutrients on WAT.  
Since we have investigated tissue biopsies of WAT, our gene expression results could 
be due to mRNA expression from any other of the WAT cells, i.e. stroma cells or 
adipocytes. We also should not forget that investigating gene expression data may not 
reflect actual changes in protein expression. Post-transcriptional and posttranslational 
activity in the WAT might change the result and subsequent metabolic effect.  
 
4.3 PAPER 3 
Follistatin is an extracellular glycoprotein that was originally identified as an inhibitor 
of pituitary Follicular stimulating hormone secretion (Ueno et al, 1987)  and later has 
been shown to be produced by many tissues. Follistatin functions as an antagonistic 
binding protein that neutralizes the bioactivity of the members of the Transforming 
growth factor beta (TGFβ) superfamily (Mather et al, 1997). Thus, Follistatin prevents 
ligand-receptor interaction of Activin, Myostatin, and bone morphogenetic proteins 
(Bessa et al; Lee & McPherron, 2001; Nakamura et al, 1990). Activin and Myostatin 
signal by binding to type II serine/threonine kinase receptor (activin type IIB) that 
partners with type I receptor (TGFβR1).  
 
We found Follistatin in a microarray study (Dahlman et al, 2005) comparing 
subcutaneous WAT gene expression between obese and lean persons. Since Follistatin 
in human WAT was not studied before we wanted to elucidate its role in human WAT 
and obesity. We showed that subcutaneous WAT Follistatin mRNA decreases with 
increasing weight, and that weight loss restores Follistatin levels. RT-q-PCR detected 
more Follistatin in subcutaneous than visceral WAT.  The SVF of WAT seems to be 
the major source. Highest levels of Follistatin were observed in CD34+/CD31- cells, 
which contain adipocyte progenitor cells, and in the capillary endothelial cell fraction. 
Isolated adipocytes had very low levels of Follistatin. We could by ELISA show that 
WAT secretes follistatin in vitro. In accordance with the mRNA-measurements in 
adipocytes there was no secretion of Follistatin from isolated fat cell cultures. 
Follistatin acts through Activin/Myostatin receptors ACVRIIB and TGFbetaR1. We 
quantified mRNA of these receptors and could show that they are expressed in WAT 
and isolated adipocytes, so the necessary machinery for Activin, Myostatin, and 
Follistatin signaling is present within WAT. 
 
Human WAT Follistatin is probably acting locally in WAT, because circulating 
Follistatin levels do not seem to be affected by obesity (Eldar-Geva et al, 2001). 
Beyond this, Follistatin has hardly been studied in humans in relation to obesity and 
related metabolic disease. By contrast, several animal studies describe changes in 
metabolic parameters like visceral fat mass, insulin sensitivity and pancreas mass that 
are of potential clinical interest. To understand potential Follistatin effects, knowledge 
concerning Myostatin and Activin effects is mandatory. Myostatin acts as a negative 
regulator of muscle growth (McPherron et al, 1997).  Loss of myostatin expression 
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results in increased muscle mass and reduced adiposity (Gonzalez-Cadavid & Bhasin, 
2004) (Schuelke et al, 2004), whereas overexpression of Myostatin leads to severe 
reduction of both muscle and adipose mass, along with cachexia (Reisz-Porszasz et al, 
2003; Zimmers et al, 2002)). Knock-out-studies by Tu 2009 showed that inactivation of 
Myostatin protects against the development of insulin resistance, proatherogenic 
dyslipidemia, and aortic atherogenesis in Ldlr−/− mice (Tu et al, 2009). A very recent 
study (McPherron et al, 2012) reduced the expectation of Myostatin inhibitors as 
treatment for obesity since mice treated with pharmacologic Myostatin inhibition 
displayed increased lean mass without loss of WAT and no effect on glucose 
metabolism. Opposing this is another recent study in which rats were subjected to 
exercise, which resulted in expression changes in Myostatin, its receptors and 
Follistatin  in both muscle and WAT (Dutra et al, 2012) highlighting the probable 
importance of this system in muscle and WAT physiology, and in metabolic disorders 
like T2D. Probably the Myostatin and Activin-inhibition will have to be tissue specific 
since recent studies (Guo et al, 2009) indicate different effects in different organs. 
 
As regards Activin, mice with a targetet deletion of the gene display developmental 
defects and early neonatal death, whereas Activin overexpression results in cancer, 
liver necrosis and cachexia (Lee & Glass, 2011; Lee et al, 2005; Matzuk et al, 1994). 
Finally, different mice knockout models have tried to elucidate the role of Follistatin. 
Deletion of Follistatin results in a number of developmental defects and early neonatal 
death (Matzuk et al, 1995). Follistatin like 3 (FSTL3) is a member of the Follistatin-
gene family. Nakatani (Nakatani et al, 2011) describes the FSTL3-KO mice. The 
FSTL3-KO mice have reduced visceral fat mass, enhanced glucose tolerance and 
increased insulin sensitivity. The reduced visceral fat mass observed in FSTL3 KO 
mice may be a primary action of excess Myostatin bioactivity resulting from loss of its 
antagonist. A Follistatin-derived peptide FS I-I that blocks Myostatin but does not 
neutralize Activin is described (Nakatani et al, 2011). FS I-I transgenic mice exhibit 
reduced fat accumulation. Adipocytes are smaller and the mice are resistant to high fat 
diet-induced obesity and hepatic steatosis. 
 
Follistatin and adipogenesis  
It has been shown that Follistatin reverses Activin and Myostatin inhibition of bovine 
adipogenesis (Hirai et al, 2007) but so far there are no human studies. To examine the 
effect of recombinant human Follistatin in human WAT we treated two human primary 
progenitor cell types with Follistatin for 21 days. Adipogenic differentiated hMSCs had 
50% more lipid content compared with controls efter 21 days of Follistatin treatment. 
Similar effects were also obtained with differentiated human preadipocytes. To 
examine Follistatin neutralizing activity of TGF beta family members we cotreated 
hMSCs with Follistatin and Myostatin under adipogenic conditions, and found that 
cotreatment appeared to reverse Myostatin inhibitory effect on adipogenesis. To further 
investigate Follistatin promotion of adipogenesis we assessed mRNA levels of some 
adipogenic markers. We investigated mRNA levels of two initiating transcription 
factors of adipogenesis, CEBP alpha and Peroxisome proliferator activator receptor 
gamma (PPARG), and one late marker, FABP4, after 21 days of chronic Follistatin 
treatment. All adipogenesis markers were increased compared to adipogenic control 
cells. Also lipid content was increased. To summarize recombinant Follistatin 
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promoted adipogenic differentiation of progenitor cells and neutralized the inhibitory 
action of myostatin on differentiation in vitro.  
Targeting preadipocyte to adipocyte conversion may be an effective way to regulate 
adipose mass. Interestingly, the expression of a Follistatin ligand, Activin B, was 
shown to be reduced by diet-induced weight loss in subcutaneous WAT from obese 
subjects (Sjoholm et al, 2006). These data suggest that obesity decreases the Follistatin 
to Activin ratio. 
To summarize down-regulation of Follistatin in obesity could aim to limit adiposity 
by inhibiting adipogenesis but, by failing to limit fat accumulation, indirectly 
contribute to hypertrophic obesity. Low Follistatin levels may result in enlargement 
of existing adipocytes at the expense of new fat cell formation. One limitation of our 
study is that we do not know if Follistatin regulates adipogenesis in humans in vivo. 
Furthermore, we cannot rule out that changes in the degree of vascularization in WAT 
that accompanies the development of obesity might account for the changes in 
Follistatin expression in relation to obesity. 
4.4 PAPER 4 
Although the cancer cachexia syndrome has received growing attention in the last few 
decades, its cause remains unknown and no known therapy is available to reverse its 
detrimental effects. In this study we aimed to search for regulatory pathways that 
accompany loss of WAT in cancer cachexia. We chose to investigate patients in a 
relatively early stage of cancer disease when the cachexia causes WAT loss and lean 
tissue is still preserved (Fouladiun et al, 2005) to avoid secondary changes that could 
exist in a more advanced metabolic situation like refractory cachexia. Our primary 
hypothesis was that changes in pathways involved in the regulation of energy 
metabolism would accompany the loss of adipose tissue. 
 
Examining the study groups it is evident that the cachexia group has a clearly reduced 
body fat mass compared to weight stable cancer patients while lean mass was 
preserved.  There were signs of systemic inflammation, a higher CRP and Interleukin 6, 
in the cachexia group. Glycerol/kg bodyweight and FFA/kg bodyweight were doubled 
in the cachexia group indicating increased lipolysis. Fat cell volume was decreased by 
cachexia. All together the metabolic changes reported in earlier studies exist also in our 
patients. 
 
We performed global transcriptome profiling by microarrays and showed that 364 
genes were downregulated and 61 genes were upregulated in subcutaneous WAT of 
cachexia patients versus weight-stable cancer patients using an FDR of 5%. By 
comparing with previously published array results from Clement (Clement et al, 2004) 
on adipocyte vs SVF expression we could see that there was a fairly even distribution 
of the regulated genes between SVF and adipocytes. The use of needle biopsy 
subcutaneous WAT, which has less SVF than surgical biopsies probably made us 
underestimate the SVF-enriched genes.  
 
Pathway analysis revealed that genes downregulated by cachexia were overrepresented 
in pathways related to extracellular matrix, actin cytoskeleton and focal adhesion. 
 36 
These changes are similar to the changes observed during voluntary weight reduction 
by hypocaloric diet in obese subjects as reported by Henegar and Kolehmainen 
(Henegar et al, 2008; Kolehmainen et al, 2008). The extracellular matrix has gained a 
lot of interest during the last years and increased extracellular matrix and fibrosis is 
observed in obesity. One theory suggests that adipocyte hypertrophy in obesity is 
limited by WAT extracellular matrix components. Excessive lipids then have to be 
stored ectopically in the liver and muscle and might increase insulin resistance. We 
could not find any enrichment of inflammatory genes among cachectic patients. A 
probable explanation might be that the systemic inflammation originates from other 
tissues than WAT. Also the amount of inflammatory genes, which in obesity is mostly 
found in the SVF, might be lower because of the needle biopsy technique. 
 
Genes in pathways regulating energy turnover were upregulated in cachectic patients, 
that is electron transport, fatty acid degradation, oxidative phosphorylation and the 
Krebs TCA cycle. These findings are consistent with the physiological finding of 
increased lipolysis and lipid oxidation in cachexia patients. Fat oxidation in the 
adipocytes could be one of several ways to get rid of the excess fatty acids generated by 
lipolysis. This would favor the metabolism of fatty acids to acetyl CoA over glucose, 
which fits with the observation that glucose administration suppresses lipid 
mobilization in normal individuals, but there is an impaired suppression in patients with 
malignant disease and continued oxidation of fatty acids (Edmonson, 1966). A potential 
mechanism to this old observation might be CIDEA, which we originally found in 
study 2 as a gene upregulated during dietary energy restriction. Our group has shown 
that CIDEA is also involved in WAT loss in cancer cachexia and this may, at least in 
part, be due to its ability to inactivate the pyruvate dehydrogenate complex, thereby 
switching substrate oxidation in human fat cells from glucose to fatty acids 
(Laurencikiene et al, 2008a).(Laurencikiene et al, 2008a). CIDEA was not differentially 
regulated by cachexia in our study which might depend on the small study group and 
the lower sensitivity of microarrays compared to RT-q-PCR, which was used by 
Laurencikiene et al. 
 
The changes in the abovementioned pathways were compared with two studies using 
whole genome microarrays to compare subcutaneous WAT gene expression between 
lean and obese individuals (Dahlman et al, 2005) (Mutch et al, 2009). Interestingly the 
changes were reciprocal as shown in table 2.  
 
In summary, examining WAT gene expression in human cancer cachexia reveals 
marked changes in pathways regulating energy turnover, extracellular matrix and 
cytoskeleton. The pathways are in many cases a mirror image to those observed with 
obesity but similar to those seen with intentional weight loss.    
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earlier shown to be expressed in WAT, but since the publication of our study in 2004 a 
few large genome wide expression studies comparing subcutaneous and omental WAT 
gene and protein expression have verified some of the results. Adipsin, Properdin, 
Serum Amyloid A, SPARC, phospholipid transfer protein (PLPT) and several 
ribosomal proteins were differentially expressed in the RDA-patient. These genes 
belong to protein synthesis pathways, immune response, cell structure, signal 
transduction and lipid, carbohydrate and amino acid metabolism pathways. Several of 
these pathways are discussed in the large studies by Wolfs (Wolfs et al, 2010) and 
Klimcakova (Klimcakova et al, 2011).  
 
To summarize the results from study 1, we can conclude that the differentially 
expressed gene products from the  RDA-study that were verified also in female and 
male obese patients showed depot related expression in 5 genes involved in gene 
pathways in immunity (Adipsin), metabolism (PLPT) and signal transduction (Ras, 
Calcyclin). These pathways and genes have later been verified by genome wide 
expression studies to be differentially expressed between depots. An unknown gene 
product was verified only in the male patients. The gene product codes for a voltage-
dependent calcium channel subunit alpha-2/delta-3 precursor. The classical roles of α2δ 
proteins are as accessory calcium channel subunits, enhancing channel trafficking. This 
gene is not studied in WAT. The finding could imply that gender differences exist in 
adipose gene expression.   
 
Our cloning of 44 differentially expressed genes in the man with extreme metabolic 
syndrome but verification of only 5 of these as differentially expressed in other obese 
patients is intriguing. Of course the sensitivity of our home-made cDNA arrays could 
be limited but other explanations are also possible. Our RDA patient probably had 
more exaggerated expression changes than our pooled healthy obese patients. This is 
supported by very interesting recent observations by Klimcacova and Wolfs concerning 
the relation between advancing metabolic disorder and gene expression changes in 
WAT. Both Klimcakova (Klimcakova et al, 2011) and Wolfs (Wolfs et al, 2010) could 
show gene expression changes that correlated with worsening metabolic traits and these 
changes were observed both in subcutaneous and omental adipose even though they 
were more prominent in omental WAT. Their findings that it is possible to some extent 
to mirror the changes in omental WAT by subcutaneous adipose biopsies is positive 
since the subcutaneous biopsies are much easier to obtain.  
 
A question we must ask is if these gene expression changes propagate to changes in 
protein expression. Perez (Perez-Perez et al, 2009) demonstrated that tissue-specific 
molecular differences in the protein secretion patterns of subcutaneous and omental fat 
depots mainly related to metabolic processes such as glucose and lipid metabolism, 
lipid transport, protein synthesis, protein folding and response to stress and 
inflammation. They suggest higher metabolic activity as well as increased cell stress in 
the omental compared to the subcutaneous fat. We can conclude that the pathways 
reported are similar to the ones mentioned above meaning that the gene expression 
changes induce protein changes and thereby probably metabolic effects.  
 
We must also consider which cell type we study. Whole WAT samples were used, and 
it is possible that some differentially expressed genes were isolated from other cell 
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types found within adipose tissue, such as endothelial cells, fibroblasts, or 
macrophages. Differential expression observed may be the result of differences in these 
cells or their proportion within a given fat depot. Studies using isolated cell fractions 
and culture techniques will be required to elucidate this question. Peinado (Peinado et 
al, 2010) showed 2010 that the protein fingerprints of isolated adipocytes from visceral 
WAT and subcutaneous WAT of lean individuals were strikingly similar, whereas 
significant differences were observed between the SVF of both fat depots in terms of 
their protein expression patterns. We did not study adipocytes and SVF separately in 
study 1 so we cannot conclude which cell type is responsible for our results. 
 
ROLE OF FOLLISTATIN IN HUMAN WAT 
 
We found Follistatin in a microarray study (Dahlman et al, 2005) comparing 
subcutaneous WAT gene expression between obese and lean persons. Since Follistatin 
in human WAT was not studied before we wanted to elucidate its role in human WAT 
and obesity. We showed that subcutaneous WAT Follistatin mRNA decreases with 
increasing weight, and that weight loss restores Follistatin levels. RT-q-PCR detected 
more Follistatin in subcutaneous than visceral WAT. The SVF of WAT seems to be the 
major source. Highest levels of Follistatin were observed in CD34+/CD31- cells, which 
contain adipocyte progenitor cells, and in the capillary endothelial cell fraction.We 
could speculate that Follistatin has a role in angiogenesis. Recombinant Follistatin 
promoted adipogenic differentiation of progenitor cells and neutralized the inhibitory 
action of Myostatin on differentiation in vitro.  
 
We believe that down-regulation of Follistatin in obesity could aim to limit adiposity 
by inhibiting adipogenesis but, by failing to limit fat accumulation, indirectly 
contribute to hypertrophic obesity. Low Follistatin levels may result in enlargement 
of existing adipocytes at the expense of new fat cell formation. This might increase 
insulin resistance leading to a worse metabolic profile. Treatments interacting with 
these pathways could possibly be used in metabolic syndrome and T2D but so far 
only murine studies exist and they show contradicting results. Probably there is a 
need to block or interact with these pathways only in selected tissues. 
 
GENE EXPRESSION IN SUBCUTANEOUS WAT OF OBESE WOMEN 
 - impact of hypocaloric diet and macronutrient content 
 
The effects of energy restriction and different diets on weight loss is widely studied by 
researchers as described in section 1.4  and there is an ongoing debate in public. Also 
the effects of diet on gene expression have evoked much interest and there is a hunt for 
the optimal diet that both reduces weight and decreases risk for the metabolic 
complications of obesity.  
 
Our second study was part of a large EU-financed multicenter study which compared 
the effects of a ten week intervention with low-fat, high-carbohydrate hypoenergetic 
diet with a moderate-fat, moderate-carbohydrate hypoenergetic diet. Both diets 
produced similar weight loss and beneficial changes in blood chemistry parameters. We 
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performed abdominal subcutaneous WAT global transcriptome profiling on a subgroup 
of patients before and after the dietary intervention. The expression of 96 genes was 
significantly influenced by hypocaloric diet. Expression of genes involved in the 
synthesis of polyunsaturated fatty acids (PUFA) was downregulated, and CIDEA was 
upregulated by hypocaloric diet. The pattern of gene expression response was almost 
identical between the two diets. 
 
We can conclude that dietary macronutrient composition is of little or no importance 
for the gene expression in human subcutaneous WAT. It is the energy restriction per se 
that is important. This finding is confirmed by others as reported in section 4.2. 
 
GENE EXPRESSION CHANGES AND GENE REGULATION IN WAT IN CANCER 
CACHEXIA  
 
The fourth study compared cancer patients with or without cachexia. The former group 
displayed reduced body fat mass, signs of systemic inflammation, and increased levels 
of circulating free fatty acids. Global transcriptome profiling followed by pathway 
analysis revealed that genes downregulated by cachexia were overrepresented in 
pathways related to extracellular matrix, actin cytoskeleton and focal adhesion. By 
contrast, genes upregulated in cachexia were overrepresented in pathways related to 
energy turnover, e.g. fatty acid degradation, and oxidative phosphorylation. 
 
We did not find differential expression of CIDEA, the gene that was most upregulated 
by hypocaloric diet in study 2. Our group has continued to elucidate the roles of 
CIDEA in metabolism and used RT-PCR in a larger group of cancer patients with and 
without cachexia. They could show that CIDEA was involved in WAT loss in cancer 
cachexia and this may, at least in part, be due to its ability to inactivate the pyruvate 
dehydrogenate complex, thereby switching substrate oxidation in human fat cells from 
glucose to fatty acids (Laurencikiene et al, 2008a). Probably the smaller group and the 
lower sensitivity of the microarray explain the different results. 
 
In summary, examining WAT gene expression in human cancer cachexia reveals 
marked changes in pathways regulating energy turnover, extracellular matrix and 
cytoskeleton. The pathways are in many cases a mirror image to those observed with 
obesity but similar to those seen with intentional weight loss.    
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upregulated in cachexia were overrepresented in pathways related to energy 
turnover, e.g. fatty acid degradation, and oxidative phosphorylation. 
 
How to proceed? Large genome-wide studies of WAT in different metabolic situations 
and different depots are beginning to clarify human WAT metabolism. So far many 
transcriptomic studies are too small and the patient phenotype not carefully described to 
give good answers to the questions asked. We need more studies of large patient 
materials of carefully phenotyped individuals studied with a systems biology approach, 
i.e at all levels including genomic, transcriptomic, proteomic, epigenomic, lipidomic 
and metabolomic level. Qualified bioinformatic handling of data and computational 
skills is obligate. When combined with adequate clinical questions and follow-up I 
think we can anticipate that this will be of large clinical importance and utility. 
This approach could be used to extend the knowledge both concerning diet effects in 
WAT, but also concerning metabolic syndrome and T2D effects on WAT with a future 
goal to provide individualized advice and treatments.  
 
Smaller laboratories could take advantage of converging genomics which proposes to 
combine the results of whole genome-scans and whole genome expression profiling by 
searching for genes differentially expressed within known regions of linkage (Bouchard 
et al, 2007). This approach has the advantage to provide a rationale when selecting 
potential candidate genes for further detailed molecular investigation. 
 
Our studies have shown changes in WAT pathways dealing with ECM, lipid 
metabolism, immune response and energy metabolism. A prominent role for 
subcutaneous WAT lipid metabolism in insulin sensitivity as recently shown stimulates 
further research (Elbein et al, 2011). The studies in this thesis is mostly descriptive. 
More functional knowledge concerning individual pathways or genes can be gained by 
using in vitro studies of human preadipocytes or hMSC using e.g. si-RNA. An 
important consideration when making WAT studies in the future is the mix of cell 
types in WAT. Analysis of the separate cellular components and their gene and protein 
expression is important, with the aim of identifying the basic features and the 
contribution of each component to different adipose tissue-associated pathologies 
(Peinado et al, 2012). The role of endothelial cells and angiogenesis in expanding 
adipose is established but so far not extensively studied (Lemoine et al, 2012). 
 
Insufficient Follistatin in obesity could possibly contribute to a hypertrophic WAT with 
large insulin resistant fat cells. Further development of tissue specific Myostatin 
inhibitors or compounds that induce Follistatin effects might be useful for treatment of 
metabolic syndrome. Further characterization by e.g. human in vitro studies are needed, 
to be followed by human in vivo trials. 
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7 SAMMANFATTNING PÅ SVENSKA 
Fetma, särskilt bukfetma, ökar risken för hjärt-kärlsjukdom och för tidig död. Cancer-
associerad kakexi karakteriseras av en ofrivillig specifik förlust av vit fettväv och 
skelettmuskel och är kopplad till sämre överlevnad och dåligt svar på kemoterapi. Vi  
tror att förändringar i fettvävens funktion bidrar till de negativa metabola 
konsekvenserna vid fetma, och dåligt sjukdomsutfall vid cancerkakexi. I denna 
avhandling har vi använt global transkriptionsprofilering (mätning av alla aktiva gener) 
på bukfettvävsbiopsier från patienter för att identifiera nya arvsanlag och signalvägar av 
betydelse för fettvävsfunktionen. Fettväven utsöndrar tusentals substanser, sk 
adipokiner som kan ha effekter både lokalt och via cirkulationen generellt i vår kropp. 
Vi har utforskat genuttryck i relation till (i) fettvävsdepot, (ii) två olika lågkalori-dieter, 
(iii) cancerkakexi jämfört med viktstabila cancerpatienter.  Härutöver har vi valt ett 
arvsanlag som är nedreglerat i fettväv från feta, Follistatin, och gjort en detaljerad 
beskrivning av dess roll i human fettväv.  
I den första studien satte vi upp en metod kallad ”Representational difference analysis” 
och identiferade en handfull arvsanlag som var olika uttryckta i subkutant bukfett 
jämfört med intraabdominell fettväv, t ex Adipsin, som ingår i komplementsystemet, 
och Fosfolipid transfer protein (PLPT), som flyttar fosfolipider mellan lipoproteiner.  
Vår nästa studie ingick i ett stort konsortium som jämförde effekten av en tio veckors 
lågkaloridiet med antingen lite fett-mycket  kolhydrater eller måttligt med fett-måttligt 
med kolhydrater. Båda dieterna åstadkom liknande viktreduktion och positiv effekt på 
blodfetter mm. Vi gjorde global transkriptionsprofilering på en subgrupp av patienter 
före och efter interventionsstudien. Uttrycket av 96 arvsanlag påverkades signifikant av 
lågkaloridiet. Det var inga skillnader i förändring i genexpression mellan de båda 
dieterna. Uttrycket av gener som reglerar syntes av fleromättade fettsyror nedreglerades 
och en gen kallad CIDEA uppreglerades av lågkaloridiet.  
I den tredje studien visar vi att Follistatin i fettväven nedregleras vid fetma och 
uppregleras av viktreduktion. Fettväven utsöndrar Follistatin in vitro. Follistatin in vitro 
stimulerar utvecklingen till mogna fettceller. Follistatin verkar genom att hämma gener 
i TGF beta familjen. Vi behandlade omogna fettceller parallellt med Follistatin och 
Myostatin och kunde då visa att Follistatin hämmade Myostatins effekt på fettceller. 
Otillräckligt med Follistatin vid fetma kan möjligen vara en orsak till hypertrof fettväv 
med stora insulinresistenta fettceller. 
Den fjärde studien jämförde cancerpatienter med och utan kakexi. Den förra gruppen 
uppvisade mindre fettmassa, systemisk inflammation, och ökade nivåer av cirkulerande 
fria fettsyror. Global transkriptionsprofilering och bioinformatisk analys visade att 
gener som var nedreglerade vid kakexi var överrepresenterade i signalvägar relaterade 
till extracellulär matrix, aktin cytoskeleton, och fokal adhesion. Gener som var 
uppreglerade vid kakexi var överrepresenterade i signalvägar relaterade till 
energiomsättning, t ex fettsyreoxidation och oxidativ fosforylering. 
  
Sammanfattningsvis associerar förändringar i fettvävens storlek med förändringar i 
fettvävsmorfologi, fettcellsantal och metabolism, samt adipokinsekretion. Mot denna 
bakgrund ger våra resultat stöd för att födans energiinnehåll, men inte dess 
sammansättning av näringsämnen, påverkar fettvävens genuttryck. Vi identifierade 
CIDEA, som sedermera har visat sig vara en viktig reglerare av ämnesomsättningen i 
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fettväven. Vi identifierade Follistatin som en ny adipokin som stimulerar 
fettcellsdifferentiering och som är nedreglerad vid fetma. Denna kunskap kan stimulera 
forskning kring behandlingar mot insulinokänslighet och diabetes. Våra resultat ger 
stöd för att cancerkakexi är associerad med remodulering i fettväven, vilket skulle 
kunna vara involverat i och bidra till fettvävsförlusten vid kakexi.  
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